HIGH-THROUGHPUT APTAMER DISCOVERY AND APTAMER INTEGRATION INTO MICROFLUIDIC DEVICES FOR RARE CELL ANALYSIS by Reinholt, Sarah Jessica,
  
 
 
HIGH-THROUGHPUT APTAMER DISCOVERY AND APTAMER INTEGRATION INTO 
MICROFLUIDIC DEVICES FOR RARE CELL ANALYSIS  
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy  
 
 
 
 
 
 
 
by 
Sarah Jessica Reinholt 
January 2017 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 Sarah Jessica Reinholt 
 iii 
 
HIGH-THROUGHPUT APTAMER DISCOVERY AND APTAMER INTEGRATION IN 
MICROFLUIDIC DEVICES FOR RARE CELL ANALYSIS 
 
Sarah Jessica Reinholt, Ph. D. 
Cornell University 2017 
 
Precision medicine is the idea where diagnostics and therapeutics are catered to each 
individual patient to provide personalized care that is optimally effective. For this to be achieved, 
technologies must exist that extensively examine samples and provide a highly detailed diagnosis 
for each patient, and processes must exist that can produce personalized drugs that specifically 
target the patient’s illness.  
Aptamers are short single stranded nucleic acids that bind to their targets with high affinity 
and specificity. Aptamers could make a substantial impact toward the goal of precision medicine. 
However, one of the main challenges preventing aptamers from reaching their potential is the 
efficient discovery of new high-affinity aptamers. Currently, aptamer selections are very time 
consuming and expensive, and often do not result in the discovery of a high-quality aptamer. The 
ability to reliably select aptamers with high affinity and specificity is paramount to the widespread 
use of aptamers. Consequently, there is great interest in improving selection technology to obtain 
high-quality aptamers much more rapidly.  
Toward this effort, we have developed a Microplate-based Enrichment Device Used for the 
Selection of Aptamers (MEDUSA) that uses affinity microcolumn chromatography. Its versatile 
96-well microplate-based design allows this device to be compatible with downstream plate-based 
processing in aptamer selections, and it lends itself to automation using existing microplate-based 
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liquid-handling systems. MEDUSA is also reconfigurable and is able to operate in serial and/or 
parallel mode with up to 96 microcolumns. We have demonstrated its use in high-throughput 
aptamer selections, characterization and optimization of the aptamer selection process, and 
characterization of previously selected aptamers. More specifically, MEDUSA was used to 
perform 96 simultaneous tests that determined the optimal target loading on resin to maximize 
aptamer enrichment for three target proteins, GFP, HSF, and NELF-E. These tests also verified 
the specificity of aptamers to these three proteins, as well as the non-specific binding of two 
suspected background binding aptamers. MEDUSA was also used to performed novel RNA 
aptamer selections to 19 different targets simultaneously. For these selections, a new, more 
efficient selection strategy was tested that greatly reduced the selection time and reagent 
consumption. Through the use of MEDUSA, aptamer selections can be optimized and performed 
in a high-throughput manner, and the success rate of novel aptamer discovery can be drastically 
improved. 
In addition to the improvement of novel aptamer discovery, developing valuable applications 
that use aptamers is of equal importance. An area of study in which aptamers could be of great 
benefit is cancer. Cancer cells are extremely diverse and contain genetic mutations that allow them 
to escape the regulatory processes necessary for the healthy function of tissues and organs. 
Moreover, there are numerous mechanisms for malignancy each with different combinations of 
genetic mutations, and cancer cells are constantly evolving, which makes cancer treatment difficult 
with varying levels of efficacy. Aptamers can be selected that bind specifically to cancer cells, and 
this can be accomplished without any knowledge about the cancer cell surface composition. We 
have developed a diagnostic device that uses cancer cell-specific aptamers to capture and filter out 
cancer cells from complex samples, such as blood. Within this same device, the captured cancer 
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cells are lysed, and their genomic DNA (gDNA) is isolated using a micropillar array. The long 
strands of gDNA are physically entangled within the array, and remain in the microchannel even 
under flow. With this device, we have demonstrated the successful capture of human cervical and 
ovarian cancer cells. In addition, we have developed a custom isothermal amplification technique 
within the microchannel that amplifies a specific gene of interest for subsequent sequencing and 
analysis to determine the presence of any genetic mutations. Following the capture of cervical and 
ovarian cancer cells, we successfully amplified the TP53 gene and sequenced a fragment from this 
gene. By comparing the sequencing results to the known human TP53 gene sequence, we 
successfully detected a point mutation in the ovarian cancer cells, whereas the cervical cancer cells 
contained the wildtype version of this gene fragment. This device can be used to amplify multiple 
genes consecutively, since the gDNA is retained, so many genes of interest in cancer can be tested 
in the same small population of cancer cells. Using our device to test patients’ cancer cells, a large 
amount of information can be provided to clinicians about each specific patient that will help them 
to prescribe the most effective treatment strategy. 
From the research presented here, aptamers could have a great impact in many areas, and 
technologies like MEDUSA would help move the field forward by enabling novel aptamers to be 
successfully discovered rapidly and efficiently. Moreover, aptamers that bind specifically to cancer 
cells in diagnostics like the one presented here would enable highly informed decisions to be made 
by clinicians about treatment options. Furthermore, aptamers could also be used in targeted drug 
delivery and therapies. Therefore, technologies such as these are examples of key steps toward 
truly personalized and precision medicine. 
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CHAPTER 1 
INTRODUCTION 
1 Aptamers and Aptamer Selection Technologies 
Antibodies are a class of proteins that are specific and bind with high affinity to their target 
antigens that are foreign and potentially harmful to the body. These affinity ligands have become 
essential in the fields of research and medicine for a wide diversity of applications. However, 
despite their widespread use, they have several limitations.[1-3] Antibodies require a living host to 
produce them in vivo, which takes months and leads to variability between batches from different 
hosts. This also means antibodies cannot be acquired to targets that do not trigger an immune 
response or are toxic to living organisms. They are also proteins, which are highly sensitive to their 
surroundings, so they must be kept in an environment (temperature, pH, salt conditions, etc.) close 
to physiological conditions during storage and usage. However, there is another class of affinity 
ligands emerging called aptamers that can overcome many of the limitations of antibodies. 
Aptamers are short, single-stranded nucleic acid molecules that bind tightly and specifically 
to their target, as illustrated in Figure 1.1. Nucleic acids (RNA or DNA) provide several advantages 
over their protein counterparts.[3] They are much less sensitive to their surroundings, and can be 
reversibly denatured and renatured, as well as lyophilized, which allows many more options for 
storage and usage. Researchers can even use modified nucleic acid bases to increase the durability 
and resistance of the aptamers to different conditions.[4-11] More importantly, aptamers are 
discovered and synthesized in vitro, which is highly advantageous. This eliminates the batch-to-
batch variation, and enables aptamers to be selected to virtually any target from single metal ions 
to whole cells and tissue.[12-14] Also, once the aptamer sequence is known, it can be synthesized 
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reproducibly very quickly and inexpensively, compared to antibodies. Furthermore, the 
environment in which they will be used can be replicated during the selection to ensure the aptamer 
will function optimally in its ultimate application. Since the beginning of aptamer research over 
25 years ago, significant work has been done in applying the use of aptamers in biosensors and 
diagnostics, imaging, and therapeutics, including targeted drug delivery.[15-28]  
 
Figure 1.1: A single-stranded nucleic acid molecule folds into a specific structure determined by 
its sequence, and this unique structure allows it to bind tightly and specifically to its target. 
 
The process by which aptamers are discovered is called SELEX, or Systematic Evolution of 
Ligands by EXponential enrichment.[29-31] This technique uses a large starting library of random 
nucleic acids (1012-1015 different sequences). These single-stranded nucleic acids have different 
primary sequences with the ability to base-pair with themselves, resulting in different three-
dimensional secondary structures that provide the binding specificity to different target molecules. 
SELEX is an iterative process that begins with a binding step in which the starting library is 
incubated with the target of interest, followed by a washing step that removes unbound or weakly 
bound sequences. The target-bound sequences are then eluted and amplified to produce an 
enriched pool ready to undergo another SELEX cycle. After several cycles, the resulting final pool 
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is dominated by the strongest binding aptamers that are identified through sequencing of the final 
pool. The SELEX method is illustrated in Figure 1.2.  
 
Figure 1.2: The SELEX method. The process begins incubation of the target molecules with the 
random nucleic acid library in a binding step. A washing step then removes unbound nucleic acid 
sequences, and the bound sequences are eluted and amplified to produce an enriched aptamer pool. 
This process is repeated until the final enriched pool is dominated by the strongest binding 
aptamers. 
 
The potential benefit of aptamer technologies is immense, and it is the aptamer selection 
process that is the ultimate limitation hindering the quality of aptamers generated for these 
applications. Although the SELEX process is straightforward in theory, there are several 
challenges associated with it. Aptamer selections tend to be very time-consuming, use large 
quantities of reagents making them expensive,[13,14] and they suffer from a low rate of success in 
that aptamers identified often have low affinity and specificity, which drastically affects sensitivity 
and background effects of any resulting technologies.[4,14] Consequently, there has been a 
significant drive to develop aptamer selection technologies to improve the methods by which 
aptamers are discovered. 
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1.1 Aptamer Selection Technologies 
A wide variety of aptamer selection techniques have been developed since the birth of the 
field in an effort to make the aptamer discovery process as optimal and effective as possible. 
Several methods are based on well-known analytical techniques, such as nitrocellulose filter 
binding, chromatography, and electrophoresis, which have been adapted to perform aptamer 
selections. Others use existing imaging technologies, such as AFM (atomic force microscopy), 
SPR (surface plasmon resonance), and FACS (fluorescence-activated cell sorting). There are 
techniques that use magnetic beads and microarrays, as well as a diversity of microfluidic selection 
techniques that have miniaturized some of these benchtop methods. Each of these techniques have 
both advantages and disadvantages, and the best technique to use depends on the target of interest 
and its ultimate application. 
1.1.1 Nitrocellulose Filter Binding 
Nitrocellulose filter binding is a simple method used in the first SELEX experiments.[29-31] 
This technique involves incubating the target and nucleic acid library, and allowing the solution to 
approach equilibrium. This solution is then filtered through a nitrocellulose filter, which binds the 
target protein and any nucleic acids that are bound to the target, while free nucleic acids pass 
through the filter.[32,33] Although this technique is straightforward and accessible to most labs, there 
are limitations. Nitrocellulose non-specifically binds proteins, so this method only works for 
protein targets, and the capture efficiency varies from protein to protein. Also, nucleic acids are 
known to non-specifically bind to nitrocellulose, especially those with multi-G motifs,[34] which 
could result in background nitrocellulose-binding aptamers dominating the final pool.  
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1.1.2 Affinity Chromatography 
An affinity chromatography approach to aptamer selections is attractive because of its 
simplicity and accessibility, and it can be performed for virtually any type of target.[31,35-39] This 
technique uses affinity resins packed within a column on which the target molecule is immobilized. 
The random library is injected into the column, and the sequences with affinity to the target bind 
and are retained within the column, while unbound sequences flow out of the column as waste. 
The target-bound sequences are then eluted from the column. Although in theory affinity 
chromatography can be used for any type of target, the target does require an affinity tag or some 
other means of immobilizing it onto a resin. Immobilizing the target on a resin can also interfere 
with aptamer binding due to steric hindrance, and it can also change the conformation of the target 
such that the selected aptamers may not behave in the same manner when the target is in 
solution.[13] Other significant drawbacks of this technique are that it requires a large quantity of 
target, and non-specific binding of the library can occur to the resin itself.[35] A feature of this 
approach is that, aside from affinity, aptamers can also be selected based upon kinetic parameters, 
such as off-rate or on-rate, by adjusting the flowrates of the binding and washing steps.[14] An 
important consideration when performing an affinity chromatography-based selection is the 
density of target on the resin.[40,41] If the target is too sparse, this increases the surface available for 
non-specific binding of sequences to the resin. If the target is too dense, steric hindrance could 
affect aptamer binding, and sequences with artificially high affinity could be selected due to 
cooperative binding where the aptamer binds weakly to multiple target molecules. 
This aptamer selection approach has been scaled down through the use of microcolumns, 
which provide several advantages over larger columns.[42] Most importantly, microcolumns allow 
the amount of target necessary to be reduced by several orders of magnitude, which allows this 
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technique to be used with targets that are difficult to purify in large quantities. They also decrease 
the amount of other reagents needed, such as resin and buffers. Decreasing the amount of resin 
drastically also reduces the surface area available for non-specific binding. Scaling down this 
technique also enables it to be multiplexed more easily. Optimizations have also been performed 
to maximize the enrichment of aptamers using the microcolumns. The density of the target on the 
resin, as well as the flowrates for each step of the selection, were optimized by monitoring the 
enrichment of a known aptamer.[42] 
The affinity chromatography-based technique was miniaturized even further in a process 
called MonoLEX.[43] Here, a capillary is used as the affinity column, and the library flows through 
the capillary. Aptamers bind to the target along the capillary, and binders are separated into groups 
by cutting the capillary at different points along its length with the idea that higher affinity 
aptamers are retained closer to the beginning of the capillary. This selection process is 
advantageous in that the amount of reagents necessary is further reduced, and it is done in a single 
round, which greatly decreases the time needed.  
1.1.3 Electrophoretic Approaches 
Aptamer selections have been performed using Electrophoretic Mobility Shift Assays 
(EMSAs).[44,45] Here, the target and random library are incubated in solution and then separated 
electrophoretically on a gel. The separation is based on their electrophoretic mobility, which is 
affected by the size, charge and shape of the molecule. The gel is imaged to see the fluorescent or 
radioactive bands, and the target-bound aptamer band is cut out of the gel, crushed, and the nucleic 
acids diffuse back into solution. This technique can be performed using tools and equipment that 
are generally readily available in most laboratories, it is straightforward, and it uses relatively little 
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target; however, there are several limitations.[13,14] This approach can only accommodate targets 
that have significantly different mobilities than the nucleic acids, which means that small 
molecules and targets with similar charge to the library are difficult to resolve on a gel. The size 
of the library can be limited due to the small volumes used, and it must be labeled with fluorescence 
or radioactivity for visualization. The selection conditions are restricted to solutions that are 
compatible with electrophoresis, and the separation step tends to be quite long, so the bound 
complexes could potentially dissociate. 
Capillary electrophoresis SELEX (CE-SELEX) has some advantages over conventional 
EMSAs.[46-51] There is no gel needed and everything is done in solution, which almost eliminates 
background binding. The process can be monitored using UV detectors, so fluorescent and 
radiolabeling is not necessary. Very small volumes are used in CE-SELEX, so the library size is 
very limited (~1012 sequences) to prevent overloading, which can make it difficult to resolve the 
bound population from the free sequences. Fractions can also be collected, which can separate the 
sequences by affinity.[52] 
A variation of CE-SELEX, called Non-SELEX, has been successfully used to generate 
aptamers.[53] This method uses capillary electrophoresis for separating bound from unbound 
sequences, but does not amplify the collected pool between binding cycles; it is simply re-injected 
into the capillary. This technique eliminates any amplification bias or non-specific amplification 
that can occur, but only a small fraction of the collected pool can be re-injected for additional 
binding and separation cycles, due to the significant dilution that occurs, and this severely limits 
the number of sequences that can be sampled. A more optimal version of this process that uses 
larger capillaries and multiple pool injections has been developed and sequence sampling was 
improved.[54] Another variation of CE-SELEX was recently developed called polymer-enhanced 
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capillary transient isotachophoresis (PectI).[55] Here, PectI was used to select high-affinity 
aptamers to cells by generating a single narrow zone of target cell-bound DNA that is very well-
separated from the free DNA. This is in contrast to conventional CE-SELEX, which typically 
results in multiple peaks. 
1.1.4 Magnetic Bead-based Approaches 
Magnetic beads have been used in aptamer selections to provide several advantages over 
resin-based affinity chromatography techniques.[56-60] In this approach, the target is immobilized 
on magnetic beads and incubated with the random library in solution. A magnet is then applied, 
which rapidly separates and concentrates the beads, and allows the solution to be aspirated, thereby 
removing the unbound sequences. Aggressive washing can be done in the same manner, and 
amplification can actually be performed in the presence of the magnetic beads, which significantly 
reduces potential losses.[13] Similarly to affinity chromatography, aptamers can be selected to any 
target that can be immobilized onto magnetic beads, which has its limitations, but unlike affinity 
chromatography, a very small amount of target is needed. Magnetic beads have also provided a 
platform for single-cycle selections through repeated vigorous washes that dissociate weakly 
bound sequences, leaving only higher affinity binders,[61] which helps to overcome the drawback 
of magnetic beads being expensive.  
Some techniques for selecting high-affinity aptamers have been developed using magnetic 
beads. Monitoring the progress of a selection is very advantageous, and a process called FluMag-
SELEX was developed that uses a fluorescently labeled library to quantify binding to the target-
immobilized magnetic beads.[62] The level of binding after each cycle of selection can be measured 
easily, since the magnetic beads can be concentrated, and this helps to monitor the progress and 
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success of the selection. A method called Aptamer Selection Express (ASExp) uses a starting 
library of double-stranded nucleic acids that must first dissociate before binding to the target.[63] 
This greatly increases the binding threshold, and only the strongest binders will favorably 
dissociate to bind to the target. To identify the bound sequences, magnetic beads coated with long 
random single-stranded nucleic acids hybridize with the anti-sense strand of the bound aptamers, 
and are removed from the solution. The selection stringency is so high that this technique only 
requires one cycle. Another single-cycle selection method called Magnetic-Assisted Rapid 
Aptamer Selection (MARAS) further exploits the benefit of bead manipulation using a magnetic 
field.[64,65] With this technique, the pre-incubated solution of target-immobilized magnetic beads 
and library is placed within a solenoid, and an alternating current is applied, which in turn creates 
an alternating magnetic field. This not only isolates the bead-bound sequences from the unbound, 
but also removes low-affinity binders from the target beads. The strength and frequency of the 
magnetic field dictate the stringency of the selection and therefore the affinity of the resulting 
aptamers. 
1.1.5 Microarrays, AFM, and SPR 
Aptamer selections have also been performed by immobilizing the target or library onto a 
surface. Microarrays have been used in which the library is immobilized on a surface in an array 
with specific sequences at precise locations on the surface.[66-70] The microarray is then exposed to 
fluorescently-labeled target, washed, and imaged to reveal the locations where the fluorescent 
target bound and identify the sequences. Using lithography, these arrays can contain up to 105 
distinct spots; however, this is an extremely small library compared to other SELEX techniques, 
so performing pre-selection cycles using a different method may be necessary. In fact, microarrays 
can be used to optimize selected aptamers by creating mutants of a specific sequence.[71,72] Using 
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microarrays also requires specialized optical equipment for imaging and reading. A major benefit 
of this technique is the ability to monitor the selection using fluorescence, which enables the direct 
observation of interactions between the nucleic acids and target, and assessment of background 
binding. One group even coupled gold nanoparticles to the immobilized library, and monitored the 
selection by measuring the generated current and/or voltage change upon binding with the target, 
which could remain label-free.[73] A selection method called Closed Loop Aptameric Directed 
Evolution (CLADE) was developed that uses a microarray to identify fluorescent target-bound 
sequences and controllably mutates these binding sequences to create a new microarray for the 
next round of selection.[74,75] This way, better binders can potentially be identified with each cycle, 
and the aptamer can be optimized. 
Other optical selection techniques have been used where the target is immobilized on a 
surface and the library is introduced in solution, which eliminates the library size restriction. A 
single-step selection technique was developed using this approach, whereby the target was 
immobilized on a cover slip and a fluorescently-labeled library was introduced.[76] Binding was 
confirmed via fluorescence detection after the surface was washed. Two SELEX techniques have 
also been developed that use AFM. A method called NanoSelection uses beads each coated in one 
specific sequence that is fluorescently labeled, which are incubated with a target-immobilized 
surface.[77] After washing, the surface is imaged using a fluorescence microscope coupled to an 
AFM to identify the location of the bound sequences, and the AFM tip is used to pluck the beads 
from the surface and transfer them to a tube where amplification can be performed. In another 
technique called AFM-SELEX, a streptavidin-coated AFM tip is used to hold a biotinylated 
nucleic acid library.[78] The library interacts with a target-immobilized surface, and the 
streptavidin-biotin interaction must be overcome in order for the sequence to bind to the target. 
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This creates a high binding threshold as the interaction between streptavidin and biotin is very 
strong. The selection was monitored by measuring the force exerted on the tip during each round, 
and an increasing force indicated increasing affinity over time. The major drawback with these 
AFM-based techniques is the limited library size. 
SPR is another technique that has been used for aptamer selections.[79-81] SPR is extremely 
sensitive and can detect very small surface changes, including binding events on a surface. A 
detector optically measures the change in refractive index of the layer very close (within ~300nm) 
to the surface of a thin metal film where surface plasmons are generated through excitement by an 
evanescent electromagnetic wave. This evanescent wave is produced by light undergoing total 
internal reflection. SPR was first used in the aptamer field as a later-round selection method after 
several rounds of nitrocellulose filter binding,[82] and has also been used as a method for 
determining aptamer binding affinity[83] and monitor binding to microarrays[84]. This ability can 
also be used to isolate aptamers based on off-rates by fractionation of the dissociation step. SPR 
has advantages over other surface-based techniques in that it is label-free, there is no library size 
restriction, and it enables monitoring of binding rates with time, which can indicate an increase in 
binding affinity in later selection rounds.  
1.1.6 Fluorescence-activated Cell Sorting 
Flow cytometry is an optical method used to count and quantitatively analyze properties of 
cells individually at very high rates. FACS uses flow cytometry to interrogate cells and sort them 
based on these properties. The cells flow in a stream to be analyzed, and this stream is broken up 
into droplets, which can then be deflected electrostatically into separate collection tubes. This 
technology has been used in aptamer selections where fluorescence measurements are used to 
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separate aptamer-bound cells from free nucleic acids and cells, as well as to separate different cell 
populations, such as live cells from dead cells, which is important since the surfaces that the 
aptamers will be binding to are different for live and dead cells.[85,86] This selection method is not 
limited to cells and has been used with targets immobilized onto beads. In these selections, each 
bead is coated with a different single sequence produced by emulsion PCR, and binding is 
determined by measuring the amount of fluorescently-labeled target on the bead.[87-89] The relative 
affinity of each sequence is also quantified directly during the selection by the relative brightness 
of the beads.  
The library size is generally restricted with this technique due to the limited throughput of 
the FACS machine, so in one method called particle display, FACS was used in later rounds of 
selection after the library has been enriched and reduced by traditional SELEX procedures.[90] To 
further demonstrate the capabilities of FACS-based SELEX, a process was also developed to 
measure aptamer expression and function inside cells.[91] These aptamers were RNA mimics of 
green fluorescent protein (GFP), and the selection used a library of ~5x108 sequences transformed 
into Escherichia coli cells containing the target molecules (non-fluorescent in an unbound state), 
and transcription was induced. The fluorescent cells were sorted from the non-fluorescent cells 
and re-cultured, and after 6 rounds of selection, highly fluorescent aptamer-target pairs were 
identified. Using FACS as a platform for aptamer selections is highly advantageous because of the 
efficient and automatic separation of aptamer-bound targets from unbound nucleic acids and 
targets, as well as the ability to easily normalize background binding. This technique can be used 
with a wide variety of targets; however, it requires highly specialized and very expensive 
equipment.  
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1.1.7 Microfluidic Approaches 
Aptamer selection techniques have been miniaturized to take advantage of the benefits of 
microfluidics. Unique selection approaches have also been developed that can only be done within 
microfluidic devices. There are many advantages to using microfluidics, including decreased 
reagent consumption, reduced contamination potential, increased surface area to volume ratios and 
therefore decreased diffusion times, and automation potential. The few drawbacks in some cases 
could be complicated fabrication and operation, expensive materials, and high fabrication costs. 
A process called micro free flow electrophoresis (µFFE) was developed using a custom 
device, and this technology has enabled electrophoretic SELEX to be performed using lower 
electric fields, shorter separation times, and larger volumes.[92] The 300-fold volume increase 
compared to typical CE-SELEX techniques enables significantly larger libraries (1014 sequences) 
to be used. Lower electric fields and shorter separation times greatly reduce the potential for 
dissociation of bound complexes, and this has also drastically decreased the dilution that occurs 
from ~6000-fold in typical CE-SELEX[46-48,93] to ~100-fold, which is beneficial for downstream 
amplification. A microfluidic chip incorporating both dielectrophoresis and electrophoresis was 
used to improve the cell-SELEX process specifically by helping to overcome the prominent issue 
of dead cells contaminating the selection and internalizing sequences non-specifically.[94] Here, 
dielectrophoresis was used to assemble only viable cells within the chip, and electrophoresis was 
used to separate the unbound and loosely bound sequences from the cell-bound sequences. 
Magnetic beads have been used in several microfluidic SELEX platforms. M-SELEX was 
one of the initial techniques described, and it begins by incubating the library with target-
functionalized magnetic beads.[95] These beads are then injected into a Continuous-flow Magnetic 
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Activated Chip-based Separation (CMACS) device that separates the magnetic beads from the 
unbound sequences using microfabricated nickel ferromagnetic structures. Using very low bead 
numbers and stringent selection conditions, high-affinity aptamers were identified in a single round 
of selection. A similar process is used in the MicroMagnetic Separation (MMS) chip, except here 
the magnetic beads are held stationary in the device while solutions flow through the channel, 
which enables a wider range of flowrates to be used to control the stringency.[96,97] To further 
increase stringency, a process called Volume Dilution Challenge (VDC) was used with the MMS 
chip during which lower affinity binders are removed from the magnetic beads.[98]  
One group has even developed a unique selection process that must be done in a microfluidic 
channel because it exploits a property of microfluidics to perform stringent partitioning of cell-
bound aptamers away from unbound sequences. This technique uses inertial microfluidic SELEX 
(I-SELEX) to focus cells into a separate fluid channel from the unbound sequences using inertial 
forces in curvilinear channels.[99] Sol-gel technology has also been incorporated into microfluidic 
devices as a matrix for target immobilization.[100-102] Sol-gels are very porous, allowing nucleic 
acids to diffuse into them and bind to the target, which is in its native state as opposed to bound to 
a surface or bead. Using microfluidics, the increased surface area-to-volume ratio allows more 
efficient sampling of the library, since binding is diffusion limited. 
One of the major benefits of microfluidic-based aptamer selections is the ability to 
incorporate multiple process steps into a single device and automate the process.[103] There have 
been several demonstrations of automated and semi-automated SELEX experiments using 
microfluidic devices. MSELEX was the initial use of microfluidics that downscaled a large 
automated SELEX system that performed the whole process from binding to amplification in a 
simpler miniaturized system.[104] Another approach incorporated more than one benchtop 
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technique to bind, wash, and transfer the bound sequences to a separate chamber.[105-107] This chip 
contains two chambers separated by a gel-filled channel with the first chamber packed with target-
immobilized beads. The nucleic acid library flows through these beads and the bound and unbound 
sequences are separated by affinity chromatography. Incorporated microheaters facilitate thermal 
elution of the bound sequences, and these sequences are electrophoretically driven across the gel-
filled channel to the second chamber, thereby preventing any contamination from the initial steps, 
and microheaters in the second chamber would allow for on-chip PCR.[107] This device was also 
demonstrated with cell-SELEX where cell culture was incorporated directly on-chip, and all 
selection steps were fully integrated to enable multiple SELEX cycles to be performed completely 
on-chip.[108] Furthermore, a selection to cells was also performed entirely at 37°C using this 
process to select aptamers that function optimally at physiological temperature.[109] 
There have been several demonstrations of microfluidic selections using magnetic beads that 
have integrated all SELEX steps on-chip and automated the device operation. These chips use 
integrated microvalves, micropumps, and micromixers to control fluid flow, and also contain 
microheaters and temperature sensors for performing on-chip amplification.[110,111] This chip 
design was further improved to enable multiple rounds of selection to be completely 
automated.[112,113] In addition to using these devices to select aptamers to proteins, they have also 
been used in selections to cells[114,115] and viruses[116]. 
Given the time-consuming nature of most aptamer selection processes, the ability to perform 
multiplexed and high-throughput selections is highly advantageous. Microfluidic approaches can 
often be easily multiplexed, since the process is contained within a single small chip. For example, 
the sol-gel-incorporating device described above was scaled up to perform selections to five 
different targets on one chip.[117,118] Scaling up processes to be compatible with multi-well 
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microplates is extremely beneficial not only for the parallelization, but also because these setups 
can be automated relatively easily using existing liquid-handling robots.[119,120] Nitrocellulose filter 
binding experiments can be performed in a high-throughput manner using 96-well filter 
devices.[121,122] Additionally, microplates have been used in selections where targets are 
immobilized on magnetic beads[119,120,123-127] or directly onto the surface of the microwell.[128,129] 
A high-throughput affinity chromatography approach using an array of microcolumns in a device 
called MEDUSA (Microplate-based Enrichment Device Used for the Selection of Aptamers) was 
recently used to perform a high-throughput aptamer selection.[130,131] This device was designed to 
directly couple to a 96-well microplate to enable high-throughput downstream processing.  
The development of high-throughput sequencing technologies has greatly benefitted the 
aptamer selection community by providing substantially more sequencing data, and this has 
enabled SELEX experiments to be performed in fewer rounds, as seen in a method called 
Quantitative Selection of Aptamers through Sequencing (QSAS) where M-SELEX was coupled 
with high-throughput sequencing to monitor multiplicity (copy number) and enrichment of 
different aptamer candidates through multiple rounds of selection.[132] M-SELEX was 
subsequently coupled to next generation sequencing with in-situ-synthesized aptamer arrays that 
enabled binding affinity measurements for thousands of aptamer candidates in a process called 
Quantitative Parallel Aptamer Selection System (QPASS).[133] High-throughput sequencing 
platforms have also recently been used for high-throughput aptamer binding assays using 
fluorescently-labeled targets. Nucleic acids are assembled on a chip and their sequences are 
determined along with their location on the chip. Then the fluorescently-labeled target is 
introduced and allowed to bind. The fluorescence intensity is measured and associated with a 
specific sequence based on location to determine the binding affinity of each individual sequence. 
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There have been three methods developed using this type of approach: HiTS-FLIP (High-
Throughput Sequencing-Fluorescent Ligand Interaction Profiling)[134] for DNA aptamers, and 
HiTS-RAP (High-Throughput Sequencing-RNA Affinity Profiling)[135] and RNA-MaP (RNA on 
a Massively Parallel array)[136] for RNA aptamers. These techniques are capable of performing 
hundreds of millions of independent binding assays, which completely eliminates the trial-and-
error-based identification of high-affinity aptamers from sequencing results alone. 
Scaling up the aptamer selection process to enable simultaneous selections to many different 
targets increases the likelihood that the selection will be successful, which is beneficial since 
selections tend to have a low rate of success.[4,14] However, despite the plethora of aptamer 
selection methods that exist, novel aptamer discovery is still the major obstacle preventing the 
widespread use of aptamers. 
2 Cell Capture in Microfluidic Devices using Aptamers 
2.1 Cell-SELEX 
Cell-SELEX is the process by which aptamers are selected to whole cells. Cancer cell lines 
are one of the most extensively studied targets for cell-SELEX. To date, many aptamers to cancer 
cells have been discovered.[137,138] One of the major benefits of cell-SELEX is that knowledge 
about the cell surface composition is not required to select specific and high-affinity aptamers. In 
fact, in many cases, the specific cell surface species to which the aptamer binds is unknown.[139] 
Consequently, cell-SELEX has been used for novel biomarker discovery.[140] Additionally, 
selecting aptamers to whole cells allows the proteins and other molecules on the cell surface to be 
in their native state, which is crucial, since it is difficult to purify and maintain recombinant 
membrane proteins in their native state.[140] Furthermore, techniques have been developed in which 
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membrane proteins are intentionally displayed in excess on live cells to ensure their native 
conformation, and cell-SELEX is performed. Aptamers discovered via cell-SELEX can be used in 
many applications, including cell labeling, cell capture, and targeted therapies. 
2.2 Microfluidic Aptamer-based Cancer Cell Capture 
Aptamers have been used as affinity capture ligands in microfluidic devices designed to 
separate and/or detect target species.[141-143] Aptamers have been used over antibodies in these 
types of applications because of their increased robustness and ease of functionalization and 
oriented immobilization. With the emergence of cell-SELEX and cell-specific aptamers, 
microfluidic devices for specific cell capture using aptamers have been developed. [144-146] 
Many aptamer-based cell capture devices use aptamers that were previously selected via 
cell-SELEX. The Tan group has developed several devices for capturing circulating tumor cells 
(CTCs) using aptamers they selected to CCRF-CEM cells (CCL-119 T-cell, human acute 
lymphoblastic leukemia), Ramos cells (CRL-1596 B-cell, human Burkitt’s lymphoma), Toledo 
cells (CRL-2631, non-Hodgkin’s B-cell lymphoma), DLD-1 cells (Duke’s type C colorectal 
adenocarcinoma), and HCT 116 cells (colorectal carcinoma).[145,147] These aptamers have also been 
used by several other research groups to develop cell capture devices and surfaces. For most 
devices, the aptamers are immobilized on the surface simply by adsorbing avidin onto the surface 
and using biotinylated aptamers. Aptamer-based cell capture was demonstrated in a capillary for 
3 different cell types individually, and achieved capture efficiencies ranging from 83.6 ± 5.8% for 
DLD-1 cells to 97.2 ± 2.8% for HCT 116 cells.[147] Using straight polydimethylsiloxane (PDMS) 
microchannels bonded to glass, CCRF-CEM cells were captured with >80% efficiency and >97% 
purity.[148] A simple PDMS channel incorporating microheaters allowed for thermal elution of 
 19 
 
captured cells and a regenerable aptamer surface.[149] Furthermore, a simple straight channel coated 
with aptamers was developed into a sandwich assay-based sensor for the detection of Ramos cells 
using aptamers conjugated to gold nanoparticles.[150] Similarly, a paper-based lateral flow assay 
was developed for the point-of-care detection of CCRF-CEM and Ramos cells using gold 
nanoparticle reporters with a limit of detection of just 800 cells.[151] A multiplex cell capture device 
was designed using an S-shaped microchannel.[152] Here, three capture regions with different 
surface-immobilized aptamers enabled the capture and isolation of three different cancer cell types 
from the same sample. 
Creating surfaces with greater surface area capable of increased aptamer immobilization 
efficiency can improve the efficacy of cell capture. For example, a device incorporating 
multivalent nanospheres, where many aptamers were immobilized onto gold nanoparticles, 
demonstrated an increased cell binding affinity by 39-fold.[153] Additionally, dendrimer-modified 
surfaces[154], silicon nanowire arrays[155,156], and hydrogels[157] have been used to capture cells 
using specific aptamers. A micropatterned surface was even developed to isolate single cells using 
aptamers immobilized in microwells.[158] A single-cell occupancy of 88.2% was achieved. For 
capturing CTCs in actual biological samples, an aptamer-coated device containing micropillars 
was designed for high-throughput capture of CTCs from whole blood.[159] This device was capable 
of processing 1 mL of whole blood in just 28 mins, and achieved 95% capture efficiency and 81% 
purity, while 93% of the captured cells remained viable.  
Aptamers selected to surface proteins that are overexpressed on cancer cells can also be used 
for CTC capture. Anti-epidermal growth factor receptor (EGFR) aptamers have been used to 
isolate human glioblastoma cells.[160] Microchannels with optimized flow rates,[161] and increased 
surface area using glass beads[162] and nanotextured PDMS[163] were developed to increase cell 
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capture efficiency. Anti-prostate-specific membrane antigen (PSMA) aptamers were immobilized 
in 51 ultra-high aspect ratio curvilinear poly(methyl methacrylate) (PMMA) microchannels to 
achieve a 90% recovery of LNCaP cells (prostate cancer).[164] This device was designed for high 
throughput, and was able to process 1 mL of sample in ~29 mins. A unique device was developed 
by Zhao et al. featuring a three-dimensional network of repeating anti-protein tyrosine kinase 7 
(PTK7) aptamers created by rolling circle amplification (RCA).[165] These long aptamer molecules 
extended tens of micrometers from the surface of the PDMS channel, which greatly increased the 
cell capture efficiency compared to monovalent aptamers, and also enabled higher throughput 
through the device. 
Using aptamers as rare cell capture ligands within microfluidic devices has many advantages 
over immobilized antibodies, and aptamers will likely continue to be used increasingly in these 
applications. However, the largest barrier to their widespread use will be discovering specific high-
affinity aptamers to new cell types. In fact, a rapid and reliable cell-SELEX process would 
revolutionize personalized and precision medicine by enabling specific targeting of each patient’s 
unique cancer cells. 
3 Dissertation Overview 
Here, I present research we have performed and devices we have developed for carrying out 
high-throughput aptamer selections and characterizations of the SELEX process, as well as 
capturing cancer cells and detecting genetic mutations. Our aptamer selection technology provides 
a platform to help overcome some of the main challenges in aptamer discovery, which will help to 
advance the field toward the widespread use of aptamers over antibodies. Equally important is the 
development of the applications in which aptamers play an essential role in providing an 
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improvement over existing technologies. Therefore, we also developed a device that uses aptamers 
to capture cancer cells, and isolates their genomic DNA (gDNA) for the purpose of genetic 
mutation analysis. 
Since aptamer selections are time consuming, expensive, and often unsuccessful, we 
developed a device that uses affinity microcolumn chromatography called MEDUSA (Microplate-
based Enrichment Device Used for the Selection of Aptamers). MEDUSA, along with a modified 
version of SELEX we developed, greatly reduce the time and reagents needed for an aptamer 
selection. MEDUSA is a high-throughput device consisting of 96 microcolumns arranged with the 
same dimensions and spacing as a 96-well microplate. This design allows it to directly couple with 
a 96-well plate enabling downstream processes to be carried out in a high-throughput manner. This 
device is also reconfigurable and can switch between the microcolumns connected in series and 
the microcolumns in parallel, making it extremely versatile and capable of many different 
conformations for different uses and experiments. Using MEDUSA, we have demonstrated 
characterization of the SELEX process and previously-selected aptamers, as well as a highly 
multiplexed aptamer selection. We performed a high-throughput experiment in which 96 binding 
tests were performed simultaneously to i) determine the optimal target loading for three protein 
targets on resin to maximize aptamer enrichment; ii) verify the partitioning efficiency and 
selectivity of previously selected aptamers; and iii) test the non-specific binding of two suspected 
background binding sequences.[130] In addition, we used MEDUSA to perform novel RNA aptamer 
selections to 19 different targets simultaneously.[131] We demonstrated the ability to perform the 
equivalent of a 10-cycle selection to 19 targets in approximately the same time as 4 traditional 
SELEX cycles to one target. Therefore, this technology could be used to establish a rapid and 
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reliable method for high-throughput aptamer discovery, which would advance the aptamer field 
and promote the widespread use of aptamers. 
Although contributing to the effort toward the efficient discovery of high affinity aptamers 
is important, developing innovative applications that incorporate them to improve upon existing 
technologies is also crucial. Therefore, our next goal was to create a platform in which aptamers 
could be used to make an impact in the challenging but critically important field, cancer. Cancer 
is a complex disease defined by genetic mutations in cells that confer growth advantage. The ability 
to identify the mutations present in a cancer patient would give clinicians information that would 
help in determining the most effective treatment strategy for that patient. Therefore, we developed 
a device that uses aptamers to capture cancer cells, or more specifically, CTCs. Following cell 
capture, the gDNA from the captured cells is isolated on-chip, gene amplification is performed, 
and this amplification product is sequenced to determine the presence of any genetic mutations. 
Using the HeLa cervical cancer cell line and the CAOV-3 ovarian cancer cell line, we have 
demonstrated the amplification and sequencing of a fragment of the TP53 gene, which is 
commonly mutated in cancer, and therefore a gene of interest. Using aptamers over antibodies for 
capturing CTCs is beneficial because they do not vary from batch to batch, they are more robust, 
and they are much less expensive to produce, which enables this technology to be used for frequent, 
non-invasive cancer cell testing. 
For the great potential impact of aptamers to be realized, novel aptamer discovery must be 
improved and valuable applications incorporating aptamers must be developed. Moreover, 
precision medicine would revolutionize healthcare, and I believe aptamers and aptamer-based 
technologies could bring us closer to enhanced diagnostics and targeted therapies, which are 
especially critical in the effective treatment of complex cancer. The research presented here 
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contributes to the goals of improved aptamer discovery and important application development, 
which are crucial steps progressing toward aptamer-based precision medicine. 
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CHAPTER 2 
HIGH-THROUGHPUT BINDING CHARACTERIZATION OF RNA APTAMER 
SELECTIONS USING A MICROPLATE-BASED MULTIPLEX MICROCOLUMN DEVICE1 
1 Introduction 
One of the main challenges in the aptamer field is the efficient discovery of new high-affinity 
aptamers. Consequently, there is interest in improving SELEX technology to obtain high-quality 
aptamers much more rapidly. New techniques include microfluidic devices that use dynamic 
behavior and flow to improve the efficiency of selections.[1-11] Furthermore, some designs 
incorporate several or all of the processing steps, and some have even been automated.[12-15] 
However, many technologies are difficult to scale for multiplexed or parallel selections. Highly 
multiplexed selections have been done using microplate technologies, which are particularly 
beneficial due to the availability of automated liquid-handling robots,[16,17] but are limited to 
traditional equilibrium solution binding[18] or interactions where the target species are bound to the 
surface of the well,[19,20] as opposed to flow and dynamic behavior achievable in microfluidic 
devices. 
Furthermore, despite the development of improved SELEX processes, little effort has been 
made to characterize and optimize SELEX technologies. Although simple theory and simulations 
have been used in an effort to predict optimal SELEX conditions,[21-26] recent binding studies have 
shown significant discrepancies with existing theory.[27,28] This has resulted in the use of empirical 
optimization for selection conditions and the development of new models.[29] These results and 
                                                 
1 This section has been adapted and reproduced with modifications to text and formatting with permission from K. 
Szeto, S. J. Reinholt, F. M. Duarte, J. M. Pagano, A. Ozer, L. Yao, J. T. Lis, H. G. Craighead, Anal. Bioanal. Chem. 
2014, 406, 2727–2732. 
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techniques will be important as new high-throughput technologies are developed to determine the 
most effective and robust aptamer selection approaches under the available parameters. 
Toward these goals, we have developed a high-throughput device called MEDUSA 
(Microplate-based Enrichment Device Used for the Selection of Aptamers). This device was 
designed to have the same dimensions as a 96-well microplate, which allows it to directly couple 
to a 96-well plate. This not only enables high-throughput aptamer selections, but also facilitates 
the use of existing plate-based methods for upstream and downstream processing, and the use of 
existing plate-based technologies for potential process automation. MEDUSA is a highly scaled-
up version of our previously-developed modular and multiplexable microcolumns, which were 
capable of being configured in both parallel and serially-connected microcolumns. MEDUSA was 
also designed to be reconfigurable in this way. Using the microcolumns, selection conditions were 
also optimized to maximize the enrichment of high-affinity aptamers.[28] Here, we demonstrate 
using MEDUSA to characterize the binding of several RNA aptamers against various targets by 
performing 96 binding tests simultaneously. Four binding studies were carried out with 8 
conditions each, and each condition was performed in triplicate to quantify the reproducibility, 
making a total of 96 binding tests. One study characterized the binding of an RNA aptamer to 
green fluorescent protein (GFP) (GFPapt)[30], over a random RNA library (N70) with increasing 
concentrations of GFP, aiming to reproduce previously-reported enrichment behavior indicating 
an optimal GFP concentration above which aptamer binding decreased likely due to steric 
hindrance. Additionally, analogous studies were performed for human heat shock factor 1 (hHSF1) 
and negative elongation factor E (NELF-E) and their respective RNA aptamers, HSFapt and 
NELFapt,[28,31] to determine optimal selection target concentrations and test the theory of steric 
hindrance. These tests showed similar optima for maximum aptamer enrichment, and 
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demonstrated the utility of MEDUSA for the characterization and optimization of aptamer 
selection parameters. The final binding study tested the specificity of the aptamers to their 
respective protein targets by connecting several of MEDUSA’s microcolumns in series and 
exposing each aptamer to 8 different targets. As expected, the aptamers only significantly enriched 
on their specific targets. Two suspected background binding sequences were also tested in this 
way, and were shown to bind to the affinity resin and the device itself. Through the use of 
MEDUSA to perform these characterization tests, critical binding behaviors and background 
binding aptamers were determined that have a great impact on the performance and efficiency of 
aptamer selections. 
Alternatively, this technology could be used for separations and sample preparation. By 
immobilizing aptamers on a resin within the microcolumns, the target of interest can be isolated 
and concentrated into a small volume. Aptamers have been used for sample preparation 
previously,[32-34] but by incorporating them into the microcolumns, very low concentrations of 
target in large volumes can be accommodated and the target can be concentrated by orders of 
magnitude into small volumes. We have demonstrated using the GFP RNA aptamer immobilized 
in microcolumns to significantly concentrate small quantities of GFP from large volumes. This 
could be easily scaled up using MEDUSA to achieve higher throughput or even multiple 
purification steps in series.  
2 Design and Fabrication of MEDUSA 
The motivation for designing MEDUSA was to construct a versatile device capable of 
performing high-throughput aptamer selections, as well as characterizations and optimizations of 
the aptamer selection process. Therefore, the basis for MEDUSA’s design is the existing 
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microcolumn technology, which minimizes reagent consumption and has been shown to be 
successful in performing novel aptamer selections and characterizations of the selection process 
to maximize aptamer enrichment.[28] Potential automation of the selection process was also taken 
into consideration, and we determined that a design based on a 96-well microplate would be ideal 
due to the availability of existing microplate-based techniques and liquid-handling robots.[16,17] 
MEDUSA was designed to have the same dimensions as a microplate with 96 microcolumns 
spaced 9 mm apart in a 12x8 grid. This allowed easy coupling to a 96-well plate (Figure 2.1) to 
continue with high-throughput downstream processes. The microcolumns can be connected in 
series or used in parallel, which provides several benefits, including the ability to perform negative 
or counter selections simultaneously, the use of one aliquot of valuable starting library for 
selections to multiple different targets, and the prevention of cross-contamination through parallel 
use during certain steps of the process. Consequently, MEDUSA was designed to be 
reconfigurable with the ability to connect the microcolumns in series or in parallel. To accomplish 
Figure 2.1: Image of MEDUSA when it is directly coupled to a 96-well microplate. 
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this, MEDUSA has a layered design consisting of layers that alter how the microcolumns are 
connected. 
Figure 2.2 shows schematics of an exploded view of MEDUSA with microcolumns 
connected in series and in parallel, as well as images of the assembled device in both 
configurations. The layers of MEDUSA are made from 2 types of material, poly(methyl 
methacrylate) (PMMA) and silicone, and the fluidic connections are made using PEEK NanoPorts 
from IDEX. The middle layer of the device (labeled “1” in Figure 2.2) is 1/2" thick PMMA and 
this layer contains the microcolumns. There are 1/16” adhesive silicone layers (labeled “5” in 
Figure 2.2) on either side of the microcolumn layer, providing a liquid-tight seal between the layers 
Figure 2.2: Schematic of the layers of MEDUSA in the order of assembly. (a) An exploded view 
of the customized device layers for configuring all 96 microcolumns to run in parallel. The flow 
path is shown in the lower boxed inset with no connections between microcolumns. The layers 
numbered 1 to 3 are the PMMA layers: the middle layer (1) containing the microcolumns, the next 
outer two layers being the caps (2) and washers (3). The outermost layers (4) consist of inlet and 
outlet ports that are bonded to the caps. The two layers numbered (5) are silicone layers, which are 
bonded to the microcolumn layer (1) to hold porous frits against both sides of the microcolumns 
to retain affinity resin and to make liquid-tight seals across the entire device. A photograph of 
MEDUSA assembled in parallel is shown in the upper inset. (b) The customized device layers for 
configuring 24 of the microcolumns to run in series. The two additional silicone layers (6) shown 
in blue, as well as the smaller complementary plastic layers (2 and 3), are specifically programmed 
to connect 3 sets of 8 microcolumns within the device. The flow path is shown in the lower boxed 
inset with microcolumns connected in series via a serpentine route through 8 microcolumns. 
MEDUSA assembled to run in series and parallel is shown in the upper inset. 
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of MEDUSA and housing 2 mm polyethylene frits that act to contain the affinity resins. Next there 
are 1/4" PMMA capping layers (labeled “2” in Figure 2.2) that contain small holes for fluid flow, 
and provide a surface on which the NanoPorts (labeled “4” in Figure 2.2) are bonded to allow 
standard connections at the inputs and outputs of the device. The outermost PMMA layers (labeled 
“3” in Figure 2.2) are 1 mm thick and contain large holes to facilitate precise placement of the 
NanoPorts. They also serve as a “washer” by distributing the forces required to hold the device 
together. For simple assembly, all layers contain 35 holes with just the center microcolumn layer 
having threaded holes to seal the device using screws (see the upper inset images in Figures 2.2a 
and b). For connecting the microcolumns in series, there are two additional non-adhesive 1/32” 
silicone layers (labeled “6” in Figure 2.2b), which contain small channels that connect adjacent 
microcolumns. There are also different capping layers to control the locations of the device inputs 
and outputs. 
The layers of MEDUSA were inexpensively and rapidly machined using a fabrication 
method that took a two-dimensional CAD for each layer and cut the material with a CO2 laser at 
10.6 µm (Universal Laser Systems VersaLaser). The intensity, speed, and density of the laser 
pulses were optimized for each thickness and type of material to maximize the efficiency, quality, 
and reproducibility of each layer. This fabrication technique is ideal for this application because it 
is inexpensive and very fast, with one device taking only about an hour to machine. It also imparts 
fewer machining defects than the manual machining used to fabricate the individual 
microcolumns, and enables easy customization of the devices by simply altering the CAD. For 
example, in this demonstration of MEDUSA, we have 3 sets of 8 microcolumns connected in 
series, and 72 microcolumns in parallel (Figure 2.2). We chose to divide the capping and washer 
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layers to enable the reconfiguration of the serially-connected microcolumns without disrupting the 
other microcolumns. 
3 Characterization of selection parameters and previously-selected aptamers using 
MEDUSA 
 
To demonstrate MEDUSA’s ability to characterize aspects of the aptamer selection process 
and selected aptamers in a high-throughput manner, four binding studies were designed. Three of 
these studies aimed to determine the optimal protein target loading on the affinity resins for 3 
different targets, GFP, hHSF1, and NELF-E, that would produce the highest aptamer enrichment. 
Properties of these proteins can be found in Table 2.1. This type of study was previously carried 
out for GFP using the individual microcolumns,[28] so repeating it here would further validate the 
findings, which showed an optimal GFP concentration of 0.6 µg per µL of resin above which the 
aptamer enrichment decreased. This trend was attributed to steric hindrance, and studying other 
proteins in this way would test this hypothesis. The 4th binding study tested the specificity of each 
aptamer, as well as two suspected background binding sequences that were present in multiple 
aptamer selection pools,[28,31,35] against 8 different targets by measuring the enrichment of each 
aptamer. Enrichments were measured using quantitative polymerase chain reaction (qPCR) 
analysis, and all of the binding studies were performed in triplicate simultaneously using all of 
MEDUSA’s 96 microcolumns. A layout of all the samples in MEDUSA is illustrated in Figure 
2.3. 
Table 2.1: Properties of the target proteins 
Protein Molecular Weight (kDa) Isoelectric Point Affinity tag 
GFP 27 5.5 Hexahistidine (n-terminus) 
hHSF1 86 5.3 GST* (n-terminus) 
NELF-E 36 8.9 Hexahistidine (n-terminus) 
UBLCP1 37 6.1 Hexahistidine (c-terminus) 
*GST tag ~ 30 kDa 
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Figure 2.3 Layout for the 96 samples in MEDUSA according to its analogous microplate position 
given by the rows A-H, and the columns 1-12. In section I, the 8 indicated targets were connected 
in series from A to H to test the specificity and partitioning efficiency of various RNA aptamers. 
This was tested in triplicate in columns 1 to 3. Sections II, III, and IV tested the effects of target 
surface concentration on aptamer enrichments. The colored triangles indicate decreasing 
concentrations of each protein from 10 µg/µL (row A) to 0.016 µg/µL (row H) in 2.5-fold dilutions. 
Section II (green triangle) aimed to confirm previous enrichment behaviors shown with GFP. 
Sections III and IV tested the same concentrations for the proteins hHSF1 (blue triangle) and 
NELF-E (red triangle) to assess the prevalence of target surface concentration effects on binding 
due to steric hindrance or other effects in aptamer selections. 
 
3.1 Recombinant protein target, RNA library, and aptamer preparation 
Recombinant proteins were expressed in BL21(DE3)-RIPL E. coli cells (Agilent 
Technologies) transformed with plasmids that encode for hexahistidine (6xHis)-tagged GFP, 
NELF-E, and UBLCP1, or glutathione S-transferase (GST)-tagged hHSF1 (Table 2.1). Two- or 
four-liter LB cultures supplemented with 100 μg/mL ampicillin were inoculated with starter LB 
culture derived from a single colony and grown at 37°C until the OD600 reached approximately 
0.6. Protein expression was induced by the addition of IPTG to a final concentration of 1 mM. 
After an additional incubation, bacteria were collected by centrifugation and the resulting pellet 
was processed using nickel-nitrilotriacetic acid (Ni-NTA) Superflow (Qiagen) or glutathione 
(GSH)-agarose (Thermo Scientific) resins according to the manufacturer’s instructions. Sodium 
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dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to verify the purity and 
quality of the final protein product. Resulting protein preps were dialyzed against 1× PBS 
(supplemented with 5 mM 2-mercaptoethanol and 0.01% Triton X-100) and stored in small 
aliquots after addition of glycerol to a final concentration of 20%. 
The random N70 RNA library used in the experiments contains ∼5×1015 sequences that are 
120-nucleotides (nt) in length and was prepared as described previously.[28] This library consists 
of a 70-nt random region flanked by two constant regions as described elsewhere.[36] hHSF1- and 
NELF-E-binding aptamers, HSFapt and NELFapt, as well as the background binding sequences, 
BBS1 and BBS2, were derived from previous multiplex SELEX experiments that used the N70 
library, and therefore contain the same 5’ and 3’ constant regions. HSFapt was previously 
identified as hHSF2-R5-2 and characterized elsewhere.[28] NELFapt was previously identified as 
Napt1.[31] The background binding sequences were identified in several previous multiplex 
SELEX experiments for dozens of target proteins.[28,31,35]] The GFP-binding aptamer, GFPapt, was 
selected using a different library with a smaller random region and different constant regions, and 
was previously identified as AP3-1.[30] For these experiments, the sequence-verified DNA 
templates for the specific aptamers and background binding sequences were in vitro transcribed 
using T7 RNA Polymerase. The transcribed RNA was subsequently treated with DNase I 
(Ambion), PAGE-purified, phenol:chlrorform and chloroform extracted, isopropanol precipitated, 
and resuspended in diethylpyrocarbonate (DEPC)-treated water. The sequences of the RNA 
aptamers, background binding sequences, and library template can be found in Table 2.2. All of 
the primers used for qPCR analysis are listed in Table 2.3, and all of the oligomers used in this 
work were obtained from Integrated DNA Technologies. 
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Table 2.2: Aptamer nucleotide sequences 
Sequence 
Name 
Nucleotide Sequence (5’-3’) 
GFPapt AGCUUCUGGACUGCGAUGGGAGCACGAAACGUCGUGGCGCAAUUGG
GUGGGGAAAGUCCUUAAAAGAGGGCCACCACAGAAGCU (84 nt) 
HSFapt GGGAAUGGAUCCACAUCUACGAAUUCAAUCAAGUCCCCAGACUCAGC
AACACUGGACAGCGAUAUGCAGAUAACCAAGACCAAUUCACUCCAGU
UCACUGCAGACUUGACGAAGCUU (117 nt) 
NELFapt GGGAAUGGAUCCACAUCUACGAAUUCCCAACGACUGCCGAGCGAGAU
UACGCUUGAGCGCCCCACUGAGGAUGCCCACGGGCGAUUGGGGCACG
GCUUCACUGCAGACUUGACGAAGCUU (120 nt) 
BBS1 GGGAAUGGAUCCACAUCUACGAAUUCCGCAGGGCUAGCCGCAUGCUC
AGGCCUGGCGGGUAGGGAGUUAGGGUAGGGAGACCAGGAGAGCUGG
CUUCACUGCAGACUUGACGAAGCUU (118 nt) 
BBS2 GGGAAUGGAUCCACAUCUACGAAUUCCGAAGCUCGUGACGGUACCUC
CUAAAAUGUCCAUGGGGAAGGGAGGGAAUGGGAAGGACAAUCGGAC
ACCGUUCACUGCAGACUUGACGAAGCUU (121 nt) 
N70 
Library 
GGGAAUGGAUCCACAUCUACGAAUUC---N70---
UUCACUGCAGACUUGACGAAGCUU 
*The underlined portions of the sequences denote the two constant regions. 
Table 2.3: Primer sequences used for qPCR analysis 
Sequence 
Name 
Forward Primer Sequence (5’-3’) Reverse Primer Sequence (5’-3’) 
GFPapt GCTTCTGGACTGCGATGGGAGCA GCTTCTGTGGTGGCCCTCTTTTAA
GGACT 
HSFapt AATCAAGTCCCCAGACTCAGCAA
CA 
CTGGAGTGAATTGGTCTTGGTTAT
C 
NELFapt CCAACGACTGCCGAGCGAGATTA
C 
GCCGTGCCCCAATCGCCCGTG 
BBS1 CGCAGGGCTAGCCGCATG GCCAGCTCTCCTGGTCTCC 
BBS2 CGAAGCTCGTGACGGTACC CGGTGTCCGATTGTCCTTC 
N70 
Library 
GATAATACGACTCACTATAGGGA
ATGGATCCACATCTACGA 
AAGCTTCGTCAAGTCTGCAGTGA
A 
 
3.2 Performing RNA selections and characterizations 
For the studies investigating the optimal protein target loading on the resin, MEDUSA was 
connected with the microcolumns in parallel, and 8 different concentrations of GFP, hHSF1, and 
NELF-E were immobilized, ranging from 10 µg of protein per µL of resin to 0.016 µg/µL in 2.5-
fold dilutions. To study the specificity of each aptamer and the non-specific binding of two 
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background binding sequences, MEDUSA was connected in series such that 8 microcolumns 
would be exposed to a single solution.  
Ni-NTA and GSH resins were washed extensively with binding buffer [10 mM N-2-
hydroxyethylpiperazine-N′-ethanesulfonic acid (HEPES)−KOH pH 7.6, 125 mM NaCl, 25 mM 
KCl, 5 mM MgCl2, and 0.02% Tween-20]. Hexahistidine-tagged GFP, NELF-E, and UBLCP1, 
and GST-tagged hHSF1, were immobilized on Ni-NTA and GSH resin, respectively. The washed 
resin was incubated with the protein at the desired concentration in a 10% slurry with binding 
buffer at 4°C with constant mixing for 1 hour. The protein-immobilized resin was then loaded into 
MEDUSA using a pipette, and MEDUSA was assembled. 
For the protein loading studies, each microcolumn was exposed to a solution containing a 
mixture of 4.95 nM N70 library and 50 pM specific aptamer, and for the specificity studies, 8 
targets in series were exposed to a mixed aptamer/N70 library solution in binding buffer [4.75 nM 
N70 library, 50 pM GFPapt, 50 pM HSFapt, 50 pM NELFapt, 50 pM BBS1, 50 pM BBS2, and 
10µg/mL yeast tRNA (Invitrogen)]. After a 10-µL aliquot of each solution was taken to use as a 
standard for qPCR analysis, 990 µL was injected at 33 µL/min using programmable multichannel 
syringe pumps (Harvard Apparatus) with MEDUSA coupled to a 96-well formatted liquid waste 
reservoir. All buffers and solutions were degassed prior to being introduced into the microcolumns. 
Following aptamer/library binding, the serially-configured microcolumns were reconnected in 
parallel, and all 96 microcolumns were washed with 3 mL of binding buffer at 300 µL/min to 
eliminate unbound and loosely-bound RNA. MEDUSA was then placed onto a 96-well microplate 
with 2-mL wells to collect the eluent. The RNA/protein/RNA-protein complexes were eluted from 
the microcolumns by flowing elution buffer [binding buﬀer + 50 mM ethylenediaminetetraacetic 
acid (EDTA pH 8.0) for selections with Ni-NTA resin; binding buffer + 10 mM glutathione for 
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selections with GSH resin; binding buffer + 10 mM maltose for selections with amylose-resin] at 
50 µL/min for 12 min.  
The eluted RNA and input standards were phenol:chloroform extracted and ethanol-
precipitated with 1 µL of GlycoBlue (Ambion) and 40 µg of yeast tRNA (Invitrogen), and the 
resulting pellets were resuspended in 20 µL of DEPC water. Four µL of the resuspended samples 
were then reverse transcribed using Moloney Murine Leukemia Virus Reverse Transcriptase 
(MMLV-RT) in two 96-well microplates. The N70 library, NELFapt and HSFapt were reverse 
transcribed using the N70 library reverse primer, and GFPapt using the GFPapt reverse primer 
(Table 2.3).  
For qPCR analysis, 10 µL of each cDNA sample was used, and qPCR was performed in 
384-well plates on a LightCycler 480 instrument (Roche) to measure the amount of RNA library 
and specific aptamer recovered from each microcolumn. The specific primers listed in Table 2.3 
were used in this analysis. 
3.3 Parallel selections reveal critical target concentration for maximal aptamer enrichments 
In previous work, we determined an optimal concentration of GFP that maximized GFPapt 
enrichment.[28] Above this concentration, there was a decrease in enrichment, and we attributed 
this decrease to steric hindrance as the protein density on the resin increased. To determine the 
prevalence of this limiting effect, we decided to use MEDUSA to reproduce the GFP results with 
additional data points, and test two other proteins, hHSF1 and NELF-E, and their respective 
aptamers. With MEDUSA connected in parallel, eight different concentrations of each protein, 
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starting at 10 µg per µL of resin and proceeding in 2.5-fold dilutions down to 0.016 µg/µL, were 
tested in triplicate (Figure 2.3, sections denoted II, III, and IV). 
The qPCR results indicating the level of binding, as well as the aptamer enrichment for all 
three proteins are shown in Figure 2.4. The flowrates used for binding in this experiment (33 
µL/min) were slightly lower than those used in the previous GFP experiment. Lower flowrates 
Figure 2.4: Recoveries and enrichments of specific RNA aptamers over the N70 library as a 
function of protein concentration. (a) The recovery of GFPapt and N70 library at various 
concentrations of GFP. Analogous data for the recovery of (b) HSFapt and N70 library from 
hHSF1, and (c) NELFapt and N70 library from NELF-E. (d–f) The calculated enrichments of the 
specific aptamers (GFPapt, HSFapt, NELFapt) over the random library. The error bars represent 
the standard deviation in recoveries or enrichments calculated for each condition performed in 
triplicate. 
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were used to increase the exposure times of the aptamers to the protein targets, since HSFapt and 
NELFapt have higher KDs than GFPapt. This was meant to increase the percentage of bound 
aptamers to hHSF1 and NELF-E. Consequently, this also increased the amount of bound GFPapt 
and decreased the amount of N70 library recovered from the GFP microcolumns (Figure 2.4a). 
This resulted in an increased enrichment of GFPapt over the N70 library. However, the 
characteristic shape of the enrichment curve was the same as previously reported, and the optimal 
GFP loading concentration of 0.6 µg/µL was reproduced (Figure 2.4d). The recovery of HSFapt 
from the hHSF1 microcolumns followed a sigmoidal shape, where the binding and enrichment 
increased steadily and then saturated at higher hHSF1 concentrations (Figure 2.4b and e). 
Interestingly, the HSFapt enrichment plateaued at the same optimal protein concentration as for 
GFP. For NELF-E, there is a very clear optimal concentration for maximum NELFapt recovery, 
and it too is at 0.6 µg/µL (Figure 2.4c). Above this concentration, there is a drastic decrease in 
NELFapt binding. Additionally, N70 library binding increased significantly with NELF-E 
concentrations above 0.6 µg/µL, which is likely due to NELF-E’s RNA Recognition Motif that 
causes it to bind RNA non-specifically.[31] These two binding trends not only result in a drastic 
decrease of NELFapt enrichment above the optimal concentration, but actually result in the de-
enrichment of NELFapt at the highest concentration tested here, 10 µg/µL (Figure 2.4f). 
The concentration studies performed here with GFP, hHSF1, and NELF-E present a strong 
case for the general steric hindrance argument of target molecules that are over-packed in solid-
phase affinity selections. Although the GFP and hHSF1 aptamer recovery curves do not show 
substantial decreases at high concentrations as with NELF-E, this binding behavior is affected by 
the selection flowrates, which is clearly evident between our old and new GFP data, so it is possible 
that this phenomenon would occur for other protein targets using different selection parameters. 
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Importantly, aptamer recoveries saturated well below 100% loading of the protein targets on the 
resin, and this indicates the presence of a limiting effect. This is most clearly revealed by NELF-
E, where the binding site for NELFapt appears to be significantly less accessible at higher 
concentrations resulting in a drastic decrease in total aptamer binding. Furthermore, a simple 
calculation assuming hard spheres for the resin predicts a critical surface protein density between 
0.1 and 1 µg/µL (depending on protein size and shape, and the resin particle size). Therefore, since 
GFP, hHSF1, and NELF-E are similarly sized, it is not surprising that the same optimal 
concentration of 0.6 µg/µL for maximum aptamer enrichment was observed. These results suggest 
that the target concentration may be the most limiting parameter for enriching aptamers in solid-
phase selections. 
3.4 Multiplex serial selections show specificity of target aptamers and background binding 
sequences 
In previous selections, we connected several microcolumns together to perform multiple 
partitions to input pools and libraries.[28] We showed the highly specific and efficient partitioning 
of GFPapt to GFP over non-specific proteins and an empty microcolumn. This serial microcolumn 
configuration is useful for multitasking nucleic acid libraries for selections to multiple unrelated 
targets, or for separating enriched pools for aptamers that bind to different distinct sites on a 
complex target.[1] Here, we decided to demonstrate the similar multiplex selection capability of 
MEDUSA by expanding the experiment to include several protein targets and their respective 
RNA aptamers: GFP and GFPapt, hHSF1 and HSFapt, and NELF-E and NELFapt. To thoroughly 
characterize the specific, non-specific, and background binding of each RNA aptamer, we also 
included a non-specific protein, UBLCP1; three commonly used affinity resins, GSH, Ni-NTA, 
and amylose; and an empty microcolumn. The four protein targets were immobilized at 0.6 µg/µL 
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onto their respective resins. MEDUSA was assembled with the eight target microcolumns 
connected in series, and the multiplex selection was carried out in triplicate to quantify the 
reproducibility of each aptamer’s partitioning efficiency and specificity. The order of the target 
microcolumns is shown in Figure 2.3, section I, and the flow was from top to bottom. 
Two suspected BBSs, BBS1 and BBS2, were also included in the starting pool along with 
the random N70 library and the specific aptamers. These BBSs were chosen from previous 
multiplex selections in which the final pools underwent high-throughput sequencing to provide 
tremendous amounts of sequencing data and the sensitivity for early detection of aptamers.[28,31,35] 
Comparing the sequencing results from many different targets revealed several identical sequences 
that were frequently enriched in earlier cycles before the target-specific aptamers dominated the 
pool. Two sequences, BBS1 and BBS2, were present in many aptamer pools, and were actually 
generally among the most enriched candidates in selections where the targets were less aptagenic 
(see Table 2.4). Based on these data, we predicted that both BBS1 and BBS2 would enrich on all 
targets by binding to the device itself and the resins, but that BBS2 would enrich more strongly 
than BBS1, especially in microcolumns containing Ni-NTA resin (similar analyses have been used 
to identify NI-NTA resin-specific sequences).[37] 
Table 2.4: Frequencies of BBS1 and BBS2 in previous selections. Summary of the number of 
times BBS1 or BBS2 has been identified in all previous selections. The numbers indicate the 
instances in which BBS1 was more highly enriched than BBS2 (or vice versa) on each target, 
grouped according to the resin on which each target was immobilized. 
Resin BBS1 Dominant BBS2 Dominant 
Ni-NTA 1 7 
GSH 3 4 
Amylose 3 4 
Empty (no Resin) 0 2 
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The results from these experiments are presented in Figure 2.5 as enrichments over the 
random N70 library in each microcolumn for the three RNA aptamers and the BBSs. The specific 
aptamers show substantial enrichment only on their intended target. GFPapt enriched an average 
of 750-fold in the microcolumns containing GFP, and actually de-enriched on all other targets with 
an average enrichment of 0.6-fold (Figure 2.5a), which reflects its high specificity to GFP. 
Similarly, HSFapt enriched an average of 232-fold in hHSF1 microcolumns and only an average 
Figure 2.5: The enrichment of RNA aptamers over the N70 library on various targets connected 
in series. The enrichment of each protein-specific aptamer, GFPapt (a), HSFapt (b), and NELFapt 
(c), and non-specific sequences, BBS1 (d), and BBS2 (e), on all eight microcolumns. The error 
bars represent the standard deviation in enrichments calculated for each target performed in 
triplicate. 
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of 2-fold on all other targets (Figure 2.5b), and NELFapt enriched an average of 262-fold on 
NELF-E and only an average of 1.6-fold on other targets (Figure 2.5c). 
The partitioning results for BBS1 and BBS2 showed agreement with the qualitative analysis 
of previous selection data.[28,31,35] BBS1 enriched on all targets as predicted with an average 
enrichment of 1.6-fold; however, enrichments were three times higher for Ni-NTA-containing 
microcolumns (Ni-NTA, GFP, NELF-E, and UBLCP1) with an average enrichment of 5.1-fold 
(Figure 2.5d). Similarly, BBS2 also enriched as predicted, with higher enrichments than BBS1 for 
all targets (Figure 2.5e). BBS2 also showed a high affinity to Ni-NTA, with enrichments of 13-
fold on non-Ni-NTA microcolumns and a striking 311-fold average enrichment on Ni-NTA 
targets. In fact, in the first Ni-NTA-containing microcolumn (blank Ni-NTA resin), the average 
enrichment was almost 1000-fold, reflecting the specificity of BBS2 for Ni-NTA. In support of 
this hypothesis, we also noticed a monotonic decrease in enrichment of BBS2 across the Ni-NTA 
microcolumns, indicating a depletion of BBS2 from the pool as it was injected across Ni-NTA-
containing microcolumns. 
Negative selections are often used to eliminate sequences from the pool that bind to 
background sources; however, they are rarely able to completely remove the sequences that bind 
non-specifically. Thus, being able to identify these BBSs in different aptamer selections enables 
us to use them as indicators of selection progress. Furthermore, these BBSs could also be used to 
generate non-specific blocking reagents that are more effective than the yeast tRNAs that are 
typically used. 
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4 Sample purification and concentration using microcolumns 
To effectively detect an analyte that exists in minute quantities, sample preparation is very 
important, and can greatly affect the limit of detection. It is highly advantageous and often 
necessary to purify and concentrate the analyte of interest prior to detecting it. This can be done 
using aptamers as the biorecognition element, and can be performed efficiently using our 
microcolumn technology. By immobilizing aptamers within the microcolumns, the target of 
interest that may exist at very low concentrations in large volumes can be accommodated and the 
target can be concentrated by orders of magnitude into small volumes. We have demonstrated this 
using an RNA aptamer to GFP immobilized on resin within a microcolumn, and concentrating a 
dilute solution of GFP into a small volume. 
4.1 Microcolumn Fabrication 
The microcolumns consist of both custom-fabricated and commercially available parts, and 
a detailed description is available elsewhere.[28] Briefly, a polyethylene terephthalate (PET) rod is 
used to construct the microcolumn body. A hole 1 mm in diameter is drilled through the center of 
the plastic rod, and a shallow 1/16” hole is drilled at one end to house a polyethylene frit, which 
will contain the resin within the microcolumn. A NanoPort (IDEX Health and Science) is bonded 
to either end of the microcolumn to accommodate standard tubing connections. Microcolumns 
with a 10-µL volume were used in these studies.  
4.2 GFP RNA Aptamer Preparation 
A DNA template for the GFP aptamer[30] that contained the T7 RNA polymerase promoter 
sequence at the 5’-end and an immobilization sequence at the 3’end was purchased as a gBlock 
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from Integrated DNA Technologies (see Table 2.5). The DNA template was PCR-amplified, 
purified using Zymo Clean and Concentrator columns, and verified by polyacrylamide gel 
electrophoresis (PAGE). The GFP RNA aptamer with the immobilization region was synthesized 
using T7 RNA polymerase (Ambion), and the DNA template was digested using DNase1. The 
RNA was purified by phenol-chloroform extraction and ethanol precipitation, verified by 
denaturing (7M urea) PAGE, and quantified using the Qubit BR RNA assay. 
Table 2.5: Aptamer and primer nucleotide sequences. 
Sequence Name Nucleotide Sequence (5’-3’) 
DNA Template: 
T7 promoter + GFPapt 
+ Immobilization region 
GATAATACGACTCACTATAAGCTTCTGGACTGCGATGGGAGCA
CGAAACGTCGTGGCGCAATTGGGTGGGGAAAGTCCTTAAAAGA
GGGCCACCACAGAAGCTTTCACTGCAGACTTGACGAAGCTT 
GFP RNA aptamer + 
Immobilization region 
AGCUUCUGGACUGCGAUGGGAGCACGAAACGUCGUGGCGCAA
UUGGGUGGGGAAAGUCCUUAAAAGAGGGCCACCACAGAAGCU
UCACUGCAGACUUGACGAAGCUU 
Forward Primer GATAATACGACTCACTATAAGCTTCTGGACTGCG 
Reverse Primer AAGCTTCGTCAAGTCTGCAGTGAAAGC 
Immobilization Probe Biotin—AAGCTTCGTCAAGTCTGCAGTGAA 
 
4.3 Purification and Concentration of GFP using Aptamers in Microcolumns 
Aptamer-immobilized resin was prepared to facilitate GFP capture and concentration (see 
Figure 2.6). Streptavidin resin was thoroughly washed with binding buffer and resuspended at a 
10% slurry. GFP RNA aptamer and biotinylated immobilization probe were added to the resin 
slurry at concentrations of 30 pmol per µL of resin and 33 pmol per µL of resin, respectively, and 
this mixture was incubated at 4°C for 1 hour with constant mixing. To prepare the microcolumn, 
a 1.5 mm polyethylene frit was inserted into the hole at the outlet of the microcolumn. The 
aptamer-immobilized resin was added to the microcolumn using a pipette, and the fluidic 
connectors were connected.  
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Figure 2.6: Schematic of aptamer-immobilized resin contained within a microcolumn for 
capturing and concentrating a target of interest in a sample. 
 
All solutions were degassed prior to being pumped through the microcolumn. To prime the 
resin, 1 mL of binding buffer was pumped through at 50 µL/min. A solution containing 25 pmol 
(~700 ng) of GFP in 1 mL of binding buffer was prepared and pumped through the microcolumn 
at 10 µL/min. A washing step was performed by pumping 1 mL of binding buffer at 50 µL/min. 
For these experiments, the elution involved using enzymes to digest the aptamers, as heat elution 
would denature the GFP proteins and may render them non-fluorescent. A cocktail of RNases, 
including RNase A, T1, and H, in binding buffer was used to digest the RNA aptamer, thereby 
allowing the GFP protein to flow out of the microcolumn. Thirty µL of this solution was pumped 
at 50 µL/min, incubated for 30 min at room temperature, and then 70 µL was pumped through at 
10 µL/min. The eluent was collected for fluorescence analysis and comparison to the initial GFP 
solution using a NanoDrop 3300 Fluorospectrometer. Figure 2.7a shows images of the 
microcolumn before and after elution. Fluorescence analysis indicated that all of the GFP was 
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recovered using this elution method (Figure 2.7b), and the GFP was successfully concentrated by 
a factor of 10 (Figure 2.7c). 
 
Figure 2.7: Fluorescence analysis of aptamer-based GFP capture and concentration. (a) 
Fluorescent images showing the microcolumn before elution containing GFP (upper photo), and 
after elution where the GFP signal has diminished (lower photo). (b) Measurement of the total 
GFP recovered by NanoDrop. (c) Measurement of the concentration change between the initial 
GFP solution pumped through the microcolumn and the recovered eluent by NanoDrop. The error 
bars indicate the standard deviation between triplicate NanoDrop measurements. 
 
5 Conclusions 
 
We believe MEDUSA could be used to improve high-throughput aptamer selections in 
productivity and efficiency. MEDUSA’s design that allows for versatility and programmability 
enables a wide variety of SELEX designs to be explored in a large-scale manner. Here, we 
demonstrated how MEDUSA can be used to thoroughly characterize affinity chromatography-
based aptamer selections. This enables this technique to be optimized to potentially outperform 
more traditional methods, while consuming fewer reagents, such as target protein, which is very 
advantageous because it allows aptamers to be selected to proteins that are difficult to purify or 
express in large quantities. Furthermore, not only can MEDUSA be used to optimize solid-phase 
affinity selections, but it can also be used to develop improved theories to better our understanding 
of these types of selections. Additionally, we demonstrated the use of microcolumns containing 
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aptamer-immobilized resin for capturing and concentrating a target of interest from a dilute 
sample. This could easily be scaled up and performed with MEDUSA, which would add sample 
preparation and separations to the list of uses for this versatile device. 
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CHAPTER 3 
HIGHLY MULTIPLEXED RNA APTAMER SELECTION USING A MICROPLATE-BASED 
MICROCOLUMN DEVICE2 
1 Introduction 
The standard SELEX process tends to be time consuming and uses a large amount of 
reagents making aptamer selections costly.[1,2] To reduce time and reagent consumption, we 
developed a modified version of SELEX we called RNA APtamer Isolation via Dual-cycles 
(RAPID).[3] This method incorporates non-amplification cycles in which the eluted RNA is 
purified and used in a second binding cycle without prior amplification of the material. To compare 
the techniques, RAPID was performed in parallel with traditional SELEX using the same targets, 
and many of the same top aptamer candidates (~10% identical aptamers in the top 10,000 enriched 
sequences) emerged. Both selections using RAPID and traditional SELEX started with a library 
of 5x1015 unique sequences, yet the RAPID selection took approximately one third the time as our 
previously-optimized SELEX process and significantly reduced the amount of reagents used.[3] In 
this approach, only one non-amplification cycle was performed between amplification cycles, so 
it remained unknown whether multiple consecutive non-amplification cycles could be successful 
and further increase the number of total binding cycles possible within a given time.  
Previously, we also developed a microcolumn technology designed for aptamer selections 
using an affinity chromatography approach. The target is immobilized on a resin packed within a 
microcolumn and the nucleic acid library is pumped through the column.[4] The scale of these 
                                                 
2 This section has been reproduced, with modifications to conform to the required format, with permission from S. J. 
Reinholt, A. Ozer, J. T. Lis, H. G. Craighead, Sci. Rep. 2016, 6, 29771. Copyright and license information: 
http://creativecommons.org/licenses/by/4.0/. 
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devices (5-30 µL resin capacity) enabled a significant reduction in reagents used for a selection. 
Flow conditions were carefully optimized to yield the highest enrichment.[4] The microcolumns 
can also be connected in series allowing multiplex selections to be performed using a single aliquot 
of the valuable random library. In later cycles, selections are performed in parallel to avoid 
potential cross-contamination of enriched libraries.[4] One drawback of these devices is they are 
tedious to use in large-scale multiplex experiments. Consequently, we designed and fabricated a 
scaled-up version of the microcolumns for higher throughput. This device, named MEDUSA 
(Microplate-based Enrichment Device Used for the Selection of Aptamers), has all of the same 
benefits as the individual microcolumns, including reduced reagent consumption and the ability to 
be reconfigured between serial and parallel connections.[5] MEDUSA was also designed with 
specific dimensions and spacing that allow it to directly couple to a 96-well microplate. This 
enabled the continued use of high-throughput techniques in any downstream processing, which 
could be automated using existing liquid-handling robots. Similarly to individual microcolumn 
devices, we have optimized selection conditions, including protein density on the resin and flow-
rates for aptamer library binding, washing, and elution, to yield the highest enrichment of 
previously-selected aptamers on their corresponding targets in a high-throughput manner.[5] 
In this article, we describe the combination of the multi-well format MEDUSA device with 
the RAPID approach to simultaneously perform multiplexed aptamer selections to 19 different 
targets, including 4 background targets. The background targets, including maltose-binding 
protein (MBP), and amylose, nickel-nitrilotriacetic acid (Ni-NTA), and anti-FLAG resins, served 
as negative selections in the first round with the microcolumns connected in series. This allowed 
us to identify non-specific sequences that bound to these resins or the MBP-tag. The primary 
protein targets are associated with regulation of transcription, RNA stability, or localization. 
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Mouse DXO and its yeast homolog (Ag Rai1) are decapping exoribonucleases that possess 
pyrophosphohydrolase, decapping and 5′-to-3′ exoribonuclease activities, and are thus implicated 
in RNA surveillance.[6,7] PNPase is a mitochondrial polynucleotide phosphorylase with 3'-to-5' 
exoribonuclease and poly-A polymerase activities, and has recently been shown to be involved in 
the import of nuclear encoded RNAs into the mitochondrial matrix, thus indicating its involvement 
in mitochondrial homeostasis.[8,9]  p23 is a molecular chaperone that initiates the disassembly of 
protein-DNA complexes, which impacts transcription factor activation potential and response time 
to environmental cues.[10] RTF1 is a subunit of the Paf1 complex (PAF1C), a multifunctional 
protein complex that associates with RNA Polymerase II and is implicated in histone modification, 
as well as transcriptional and posttranscriptional gene regulation.[11] NELF-E is a component of 
the NELF complex that negatively regulates elongation of transcription by RNA polymerase II.[12] 
The remaining 8 protein targets are various enzymes and enzymatic subunits involved in histone 
modification that are key features in epigenetic transcription regulation. These proteins are: TIP60-
Chromo, GCN5-GNAT, MOF-Chromo, UTX-JMJC, JMJD2-Clav., JMJD2-JMJC, ASH1-BAH, 
and Trx-ZnFinger. 
We exploited the reconfigurable design of the MEDUSA device to enable multiple selections 
to be performed using just 2 aliquots of library, and its microplate-based dimensions to perform 
downstream processes such as reverse transcription, PCR, quantitative PCR (qPCR), and 
transcription in a 96-well plate format. Encouraged by our earlier results with RAPID where 
amplification and non-amplification cycles are alternating, we decided to take our RAPID 
approach a step further by increasing the number of non-amplification cycles with later rounds of 
selection to drastically reduce the time and reagents needed for the selection. We performed the 
equivalent of a 10-cycle SELEX (with only 4 of these cycles requiring amplification) to 19 targets 
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in about the time it would take to perform 4 cycles of conventional SELEX to one target. Analysis 
of high-throughput sequencing results allowed us to identify potential aptamer candidates, and 
many of these candidate aptamers were verified to bind the corresponding target proteins with a 
dissociation constant (KD) in the nanomolar range. In addition, further inspection of aptamer 
sequences enriched for DXO led us to identify aptamers that not only bind, but also resist DXO’s 
exoribonuclease activity. Furthermore, in studies monitoring the degradation of a 30-nt RNA 
substrate by DXO, the aptamers demonstrated significant inhibition of DXO activity. These and 
the aptamers to other proteins could be used for inhibiting target protein function, and the 
sequencing data provides a rich source of information to understand the biology of these target 
proteins and perhaps uncover novel functions (e.g. RNA interaction) and specificity. 
2 Materials and Methods 
2.1 Target Protein Preparation 
MBP-tagged protein domains were purified from E. coli Bl21 (DE3) RIPL strain using 
amylose resin (NEB) according to the manufacturer’s recommendations. Briefly, for each protein 
the bacteria were grown to an OD600 of 0.6 in 1 L of LB media supplemented with 100 µg/mL of 
ampicillin, and induced with 200 µM IPTG. Induction cultures were then incubated at 18-22°C for 
12-14 hours with 250 rpm shaking. Bacteria pelleted at 3500 rpm and 4°C for 30 min were lysed 
in MBP buffer (20 mM Tris-Cl pH 7.5, 300 mM NaCl, 1 mM EDTA, 5 mM BME) supplemented 
with 0.1% NP-40, 1 mg/mL Lysozyme, and 1X Protease Inhibitor Cocktail (Roche). After a 15-
min incubation on ice, lysates were sonicated on ice 3 times for 30 s each using a Branson Cell 
Distributor with a microtip, and cleared by centrifugation at 20,000 x g and 4°C for 45 min. Cleared 
lysates were applied to 1 mL of pre-washed amylose resin and allowed to pass through the column 
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under gravity flow. Protein-bound resin was washed 3 times with 10 mL of MBP buffer, and the 
proteins were eluted in five 1-mL fractions using MBP buffer supplemented with 10 mM maltose. 
Protein concentration was measured by Bradford Protein Assay (Bio-Rad) against a BSA standard, 
and the purity of each protein preparation was determined by sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) and Coomassie Blue staining. One or two fractions 
that had the highest protein concentration (often >1 mg/ml) and were relatively pure (>80% pure 
estimated from Coomassie stained gel) were supplemented with 10% glycerol, aliquoted, and 
stored at -80°C. The maltose used for elution was not dialyzed, since most proteins precipitated 
out during dialysis, and re-binding of these proteins was done at very dilute conditions (>100-fold 
dilution, thus <0.1 mM maltose), which permitted efficient re-binding of the purified proteins to 
the amylose resin for the aptamer selections.  
Hexahistidine (6xHis)-tagged NELF-E was purified as described previously.[12] All other 
target proteins were kindly provided by others: 6xHis-tagged DXO and Ag Rai1 by the Tong Lab 
at Columbia University, 6xHis-tagged wildtype and S448A mutant versions of PNPase by the 
Teitell Lab at the University of California, Los Angeles, 6xHis-tagged p23 by the Freeman Lab at 
the University of Illinois, and FLAG-tagged RTF1 by the Marazzi Lab at Mount Sinai Graduate 
School for Biomedical Sciences.  Protein concentrations ranged between 0.3 mg/ml (FLAG-RTF1) 
and 34 mg/ml (PNPase). Supplementary Table S2 contains detailed information for all target 
proteins and tags used in the MEDUSA selections. 
2.2 Target Protein Immobilization on Affinity Resins 
For each cycle of the selection, fresh protein-immobilized resins were prepared. Amylose, 
Ni-NTA, and anti-FLAG resins were washed thoroughly with binding buffer (25 mM Tris-Cl pH 
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7.5, 100 mM NaCl, 25 mM KCl, and 1 mM MgCl2) prior to target immobilization. MBP-, 6xHis-
, and FLAG-tagged protein targets were immobilized onto amylose, Ni-NTA, and anti-FLAG 
resins, respectively, by incubating the proteins at a concentration of 0.6 µg/µL of resin with the 
resin in a 10% slurry in binding buffer. The target resins were incubated for 1 h at 4°C with constant 
mixing. A list of targets and the order in which they were connected in series for the first round of 
selection can be found in Figure 3.1b. 
2.3 Library and Primers 
The random RNA library (N70) used in this selection contained ~5x1015 RNA sequences of 
120 nt in length, which was transcribed in vitro from a DNA library that was chemically 
synthesized by GenScript. The RNA library consisted of a 70-nt random region flanked by two 
constant regions (5’-GGGAAUGGAUCCACAUCUACGAAUUC- N70 -
UUCACUGCAGACUUGACGAAGCUU-3’) as described elsewhere.[13] The forward and reverse 
primers used for PCR, qPCR, and reverse transcription were T7pro-AptLibConsFOR, 5’-
GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA-3’, and AptLibConsREV, 5’-
AAGCTTCGTCAAGTCTGCAGTGAA-3’, respectively. The forward oligo contains the T7 promoter 
sequence (underlined) used for transcription of the DNA template to RNA, and a shortened version of 
the original forward constant region to reduce primer dimer formation. These primers and other oligos, 
including the gBlock templates of the candidate aptamers, were purchased from Integrated DNA 
Technologies. 
2.4 MEDUSA Fabrication 
A description of MEDUSA’s components, as well as its fabrication, is described in detail 
elsewhere.[5] Briefly, a MEDUSA consisting of 48 microcolumns arranged in a 4x12 grid (Figure 
 67 
 
3.1a) was fabricated using a CO2 laser at 10.6µm (Universal Laser Systems, VersaLaser) to cut the 
poly(methyl methacrylate) (PMMA) and silicone layers. Each microcolumn had a 10-µL volume 
capacity, and fluidic connections were made using standard microfluidic connectors purchased 
from IDEX. This device was assembled such that it could be reversibly configured between the 
microcolumns connected in series or in parallel.  Between rounds of selection, the device was 
washed extensively with 1 M KOH, 1 M HCl, and 1x binding buffer separated by DEPC water 
washes, and reused for all subsequent rounds. 
2.5 RNA Aptamer Selection Process 
All solutions were degassed and introduced into the device via a standard syringe pump 
(Harvard Apparatus). The selection consisted of 4 rounds ending in pool amplification, with a total 
of 10 binding cycles by incorporating increasing numbers of non-amplification cycles in each 
round (Figure 3.1c). The flow parameters used in each round of the selection are summarized in 
Table 3.1.  
Table 3.1: Selection Parameters 
Round 
Number of 
Binding Cycles 
Binding Step 
Parameters 
Washing Step Parameters 
Elution Step 
Parameters 
1 1 1mL at 1µL/min 3mL at 1µL/min 400µL at 50µL/min 
2 2 1mL at 10µL/min 1mL at 1mL/min, 2mL at 70µL/min 400µL at 50µL/min 
3 3 1mL at 10µL/min 1mL at 1mL/min, 2mL at 70µL/min 400µL at 50µL/min 
4 4 1mL at 10µL/min 1mL at 1mL/min, 2mL at 70µL/min 400µL at 50µL/min 
 
In the first round of selection, MEDUSA was configured with microcolumns connected in 
series, and two aliquots of the N70 RNA library were used for 19 total targets. The order of target 
proteins in each series is shown in Figure 3.1b. The target-immobilized resins were loaded into 
MEDUSA using a pipette, with 10 µL of resin in each microcolumn. With MEDUSA connected 
in parallel to prevent target contamination, the resin-packed microcolumns were washed and 
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primed by flowing 1 mL of binding buffer at 100 µL/min, which removed any unbound proteins 
from the microcolumns. The random RNA library was diluted to 1 mL in binding buffer, and heat 
denatured at 65°C for 5 min. The library was allowed to slowly cool to room temperature while 
degassing, and finally 200 units of RNase inhibitor (SUPERase•In, Ambion) were added to each 
library. A 10-µL sample of each library was collected and used as a standard for qPCR analysis. 
MEDUSA was reconnected in series for the binding step, and the libraries were pumped at 1 
µL/min in the first round. MEDUSA was then reassembled into a parallel configuration for the 
remaining selection steps. After RNA library binding, each microcolumn was washed with 3 mL 
of binding buffer at 1 mL/min. To elute the protein-RNA complexes from each microcolumn, 400 
µL of elution buffer [100 mM ethylenediaminetetraacetic acid (EDTA) (for Ni-NTA resin), 50 
mM maltose (for amylose resin), and 100 µg/mL 3x FLAG peptide (for anti-FLAG resin) in 
binding buffer] were pumped at 50 µL/min, and the eluent was collected in a 96-well microplate 
coupled to MEDUSA. The eluted RNA was purified by phenol-chloroform extraction, and 
concentrated via ethanol precipitation with 1 µL of GlycoBlue (Ambion) and 40 µg of yeast tRNA 
(Invitrogen). The resulting pellet was resuspended in RNase-free water. This RNA pool 
subsequently underwent either another binding reaction (non-amplification cycle), or immediate 
reverse-transcription and PCR amplification. 
 The standards and resuspended pools were reverse transcribed using Moloney Murine 
Leukemia Virus Reverse Transcriptase (MMLV-RT). Residual RNA was digested using a cocktail 
of RNases, including RNase H, A, and T1 (Invitrogen). Approximately 3% of the cDNA from 
each pool was used to determine the RNA recovery compared to the initial quantity of RNA at the 
beginning of the round via qPCR. The remaining cDNA was PCR-amplified, and purified using 
DNA Clean & Concentrator spin columns (Zymo Research). A fraction of the purified DNA was 
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used for transcription with T7 RNA polymerase (Invitrogen) to produce the RNA pools for the 
next round of selection. Following transcription, the template DNA was digested using DNase I 
(Ambion), and the RNA was phenol-chloroform extracted and ethanol precipitated. The purified 
RNA pools were verified by denaturing (7M Urea) PAGE for purity and length, and quantified via 
Qubit BR RNA assay (Invitrogen). 
 In rounds 2, 3 and 4 of the selection, 50 µg of the enriched RNA pools were used, and an 
increasing number of non-amplification cycles were incorporated in which the eluted RNA was 
purified by phenol-chloroform extraction, ethanol precipitated, and directly subjected to the next 
binding cycle without amplification. The flowrates were increased slightly to allow multiple 
binding cycles to be performed within a single day (see Table 3.1). 
2.6 High-Throughput Sequencing of Pools 
A small amount of cDNA from each final pool was PCR-amplified using primers containing 
unique 6-nt barcodes and the necessary adapters for the HiSeq 2500 (Illumina) sequencing 
platform operated in Rapid Run Mode. The sequencing data was analyzed with readily available 
software. Briefly, the sequencing data was quality filtered, barcode split, trimmed of constant 
regions and barcodes, and collapsed using programs included in the FASTX toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/). The resulting library of sequences was first clustered 
using UCLUST software, part of the USEARCH software,[14] at a 90% sequence identity threshold. 
To identify the abundance of all aptamer clusters in every target library, the original aptamer 
clusters were then reclustered as before, and the total number of sequences in each cluster in every 
target library was tabulated. Only a representative aptamer sequence, the most abundant sequence 
in a given cluster, is listed for a cluster. Sequences with sufficient multiplicity (defined as: number 
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of sequences in a cluster / number of total sequences in the library), enrichment (defined as: 
abundance in the last round or cycle / abundance in an earlier round or cycle), and specificity 
(defined as: abundance in the target-specific library / abundance in all other libraries) were 
identified as probable aptamer candidates. 
2.7 Motif Search using MEME 
To identify motifs, 5-20 nt RNA sequences that were enriched in a selected RNA pool and 
present in the top 3000 aptamer clusters were subjected to analysis by the MEME program of the 
MEME Suite (http://meme-suite.org/).[15,16] The E-value, representing the statistical significance 
of the identified motif, is estimated by MEME as the log likelihood ratio of finding an identical 
motif with the same width and site count in a similarly sized set of randomized sequences with 
identical base composition. Small E-values (up to 0.05) are considered significant, with smaller 
ones being the most significant. Motifs identified by MEME for target proteins were found to be 
specific and not identified in other target pools. 
2.8 Binding Affinity Determination via EMSA 
To test the binding capability of the aptamer candidates and determine the dissociation 
constant, electrophoretic mobility shift assays (EMSAs) were performed for each candidate. The 
RNA aptamer candidate was fluorescently labeled at the 3’ end with fluorescein isothiocyanate 
(FITC).[17] With the quantity of RNA constant, a series of protein concentrations were incubated 
with the labeled aptamer candidate for 60 minutes. These samples were then run at 4°C on an 
agarose gel (1.5% agarose, 0.5x TBE, 1 mM MgCl2), and imaged using a fluorescence scanner. 
The gel images were quantified using ImageJ, and the resulting curves were fitted to the Hill 
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Equation using Igor Pro 5.04A to determine the KD. For many of the aptamers, a second EMSA 
was performed, and the data from both experiments were merged and fitted to the Hill Equation. 
2.9 Analysis of DXO Aptamers Resisting Exoribonuclease Activity and Acting as Inhibitors 
Body-labeled RNA aptamers were generated by in vitro transcription with T7 RNA polymerase 
and [α-P32]UTP (Perkin Elmer), and purified by RNase-free Micro Bio-Spin P-30 columns (Bio-
Rad). Exoribonuclease assays were performed as described elsewhere.[7] Briefly, radiolabeled 
RNA aptamers (10,000 cpm in RNase-free DXO buffer: 50 mM NaCl, 5 mM MgCl2, 20 mM Tris-
Cl pH 8.0, 0.5 mM DTT, 0.025 mg/mL UltraPure BSA) were first heat-denatured at 70°C for 5 
min and renatured at room temperature for 15-30 min. They were then incubated with 1 µM 
recombinant DXO enzyme (in DXO buffer) for various durations at 37°C. For testing the inhibition 
of DXO 5’-3’exoribonuclease activity by RNA aptamers, DXO was first equilibrated with RNA 
aptamers at room temperature for 5 min. 3’-Cy5-labeled 30-nt RNA substrate (Dharmacon)24 was 
then added, and the reaction was incubated at 37°C for 2 hours. The final reactions contained 1 
µM DXO, 20 nM 3’-Cy5-labeled RNA substrate, and various concentrations of DXO RNA 
aptamers (0-1100 nM) in DXO buffer. After incubation, each reaction was mixed with an equal 
volume of 2X Gel Loading Buffer (Ambion), heat denatured at 75°C for 5 min, and run on 8 or 
10% denaturing polyacrylamide gels. After gel running, the gel was either dried on Whatman 
paper, exposed to a Phosphorimager screen, and the screen was imaged using a Typhoon 9400 
scanner, or the gel was EtBr stained and imaged with a Typhoon 9400 scanner. Quantification of 
these images was performed using ImageJ software, and the data analysis was carried out either in 
Microsoft Excel or in GraghPad Prism6 software. 
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3 Results and Discussion 
3.1 MEDUSA as a Platform for Highly Multiplexed Aptamer Selections 
MEDUSA was designed for high-throughput aptamer selections and characterizations of 
the SELEX process using a microplate-based format allowing high-throughput downstream 
processes to be performed. This standardized format greatly increases the speed at which these 
processes are performed, and allows for potential automation of the aptamer selection process 
through the use of existing liquid-handling robots.[13,18] Multiplexing is especially beneficial with 
aptamer selections because it increases the likelihood of success per selection, where low success 
rates (30%) have been previously reported.[1,19]   The SELEX process is also very time-consuming, 
often taking several weeks to months to complete,[2] so performing many selections simultaneously 
is extremely advantageous.  
 MEDUSA is capable of connecting interchangeably between parallel and serially-
connected microcolumns during a selection (Figure 3.1a). This ability provides additional benefits, 
including the incorporation of in-line negative or counter selections and efficient use of the starting 
library. Here, just two aliquots of the random RNA library was used in selections to 19 different 
targets (Figure 3.1b), which saved significant cost as the library is very expensive to synthesize. 
Additionally, performing aptamer selections using a microcolumn approach significantly reduces 
reagent consumption, most importantly the amount of target needed. This is beneficial when the 
target might only be available in limited quantity, especially for proteins that cannot be generated 
recombinantly in bacteria, but instead are purified from a mammalian cell line (e.g. FLAG-RTF1). 
Each cycle in these selections required just 6µg of protein, which allowed selections to be carried 
out on protein targets that were difficult to purify in large quantities. Therefore, MEDUSA can 
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provide advantages over other techniques that help to overcome some of the limitations frequently 
observed during aptamer selections. 
 
Figure 3.1: Schematics of the selection device and selection process. (a) The schematics describe 
the fluid path through the MEDUSA device in serial (left) and parallel (right) configurations, while 
the lower panels show images of the device in each configuration. (b) The list of targets in the 
order in which they saw the initial RNA library in a serial configuration. All the proteins in Lane 
1 have an N-terminal MBP-tag, and in Lane 2 an N-terminal 6x His-tag, except RTF1, which has 
an N-terminal FLAG-tag for immobilization on amylose, Ni-NTA, and anti-FLAG resin, 
respectively. (c) The aptamer selection process beginning with a random RNA library, proceeding 
with 4 rounds of SELEX incorporating increasing numbers of non-amplification cycles prior to an 
amplification cycle, and ending with high-throughput sequencing of the enriched RNA pools. Ten 
cycles of selection were performed, starting at Round #1-Cycle #1 (R1C1) and ending at Round 
#4-Cycle #4 (R4C4). 
 
3.2 Incorporation of Multiple Non-Amplification Cycles to Improve Selection Efficiency 
Because the conventional SELEX process is time consuming, many approaches have been 
proposed to decrease the time required for a selection.[1,2] RAPID-SELEX was previously 
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developed by our group, which incorporates a single non-amplification cycle between cycles that 
include amplification of the enriched aptamer pool.[3] Selections using RAPID-SELEX identified 
RNA aptamers in one third of the time compared to conventional SELEX. To further exploit the 
benefits of this process, additional non-amplification cycles were incorporated during the 
selections presented here. The selection consisted of 4 rounds ending in pool amplification, with a 
total of 10 binding cycles by incorporating increasing numbers of non-amplification cycles in each 
round (Figure 3.1c). This allowed 10 binding cycles to be carried out in the same amount of time 
as 4 cycles of conventional SELEX, and with our process this took less than 4 weeks. This also 
dramatically reduced the cost of the selections by significantly reducing the amount of reagents 
used for reverse transcription, PCR amplification, and in vitro transcription. Including non-
amplification cycles was also found to lead to a faster sequence convergence over traditional 
SELEX.[3] 
3.3 qPCR and High-throughput Sequencing Results 
Quantitative PCR was used to measure the amount of RNA recovered after each binding 
cycle relative to the amount of RNA in the starting pool for each round. Figure 3.2 shows qPCR 
results measuring the percent recovery of RNA after each of the 4 cycles in Round 4 relative to 
initial concentration of RNA at the beginning of the round for all of the targets in this selection. 
All 19 targets showed the same trend with decreasing RNA recovery after each cycle. These results 
indicate that despite multiple consecutive binding cycles without amplification, a sufficient 
amount of RNA was recovered to warrant continuation of the selections. Since this trend was 
observed for every target, it can be concluded that this modified SELEX process can likely be used 
for any target. Furthermore, the targets with the highest affinity aptamers identified from the 
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selection (DXO, TIP60-Chromo, and NELF-E) showed the highest RNA recovery during Round 
4, suggesting that sequences with high affinity for these targets were being enriched. 
 
Figure 3.2: qPCR results indicating the percent recovery of RNA after each binding cycle in 
Round 4 relative to the initial RNA concentration at the beginning of the round. The error bars 
represent the standard deviation for triplicate measurements. 
 
To identify candidate aptamers for each target protein/domain and assess their enrichment, 
the final RNA pools [Round #4-Cycle #4 (R4C4)] and the pools after Round #3-Cycle #3 (R3C3) 
for every target were analyzed via high-throughput sequencing. All intermediate pools for four of 
the targets were also sequenced (Appendix A, Table A1). This way, the presence of specific 
sequences can be monitored throughout the selection process, and help us better characterize the 
selection process with the MEDUSA device and modified RAPID-SELEX protocol. 
Unfortunately, of the four targets that were chosen for detailed analysis by high-throughput 
sequencing only one target, TIP60-Chromo, yielded sufficient aptamer convergence in the final 
and earlier rounds to be analyzed. Contrary to earlier reports, we did not observe that certain 
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aptamers enriched in earlier cycles are replaced by other aptamers in later cycles (Appendix A, 
Figure A1).[20] This difference could be a direct result of PCR-induced bias in conventional SELEX 
methods, where amplification of enriched pools is carried out after every cycle. Our RAPID-
SELEX method greatly reduces the potential for such a bias, since amplification of enriched pools 
were carried out minimally, just 4 times in a 10-cycle selection.  
Upon examination of the high-throughput sequencing results, sequences that could not be 
identified as an aptamer candidate (i.e. the constant regions were missing) were discarded, though 
a few still made it through our analysis pipeline (Appendix A, Figure A1). Sequences with 90% 
sequence similarity were grouped into clusters. A total of 40 aptamer candidates for 8 of the 15 
protein targets were selected for further testing of specific binding by EMSA. Five candidates were 
chosen for each target protein/domain based on having i) the highest multiplicity in the final RNA 
pool, ii) the highest enrichment from the R3C3 to the R4C4 pools, and iii) the highest specificity, 
in that these sequences were not highly abundant in any other RNA pool. The other 7 protein 
targets did not yield any candidate aptamers that were deemed appropriate for further testing, 
which would be sequences that had both high multiplicity and high specificity after 10 cycles. The 
selection was arbitrarily stopped after 4 rounds and 10 cycles because this was a proof-of-concept 
selection to demonstrate MEDUSA and the new RAPID approach. Additional cycles could be 
quickly performed, and would likely yield aptamers to more of these targets, as well as aptamers 
with improved affinity. The sequencing results highlight another advantage of multiplexing in that 
background binding or non-specific sequences can be easily identified and discarded from the pool 
of potential aptamer candidates. Previously, sequences that bind to the device and resins have been 
identified,[5] so these non-specific and other cross-reacting sequences can be identified and 
eliminated to save time and cost. 
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3.4 Aptamer Candidate Testing 
EMSAs were performed to test the binding of candidate aptamers to their respective targets 
and determine the dissociation constants. Results for 5 of the aptamer candidates can be seen in 
Figure 3.3a, as well as dissociation constants for all of the aptamer candidates tested that showed 
binding using this technique (Figure 3.3b). A total of 25 aptamers were found for 5 different targets 
with dissociation constants in the nanomolar range (EMSA analyses shown in Appendix A, Figure 
A2), and it is likely that further optimization of the aptamer sequence would improve their affinity. 
Figure 3.3: Binding analysis of candidate aptamer sequences. (a) Measurement of dissociation 
constants for aptamers to 5 different protein targets by EMSA experiments. The data were fitted 
to the Hill Equation to determine the KD. (b) A list of the dissociation constants for all of the 
aptamer candidates tested and their multiplicity ranking in their respective final (R4C4) pools. A 
complete list of the top 3,000 aptamer clusters for final pools of each target is provided in 
Supplementary Dataset 1. 
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The copy numbers (multiplicity) of the selected aptamer candidates varied greatly, and did 
not predict whether the aptamer would bind nor did they correlate with the determined KD (Figure 
3.3b). There were highly abundant sequences that did not bind to their targets, and sequences with 
only a few copies that did bind, so it is possible that more aptamers exist in the selected pools. 
From these results, we conclude that sequencing will indicate what sequences are present in the 
pool and their abundance, but it will not necessarily predict binding or affinity. High-throughput 
binding assays of target proteins to all aptamers could be used to provide a more comprehensive 
identification of the highest affinity aptamers in a selected pool.[21,22] 
 
3.5 Studying Protein Function through Aptamer Selection 
To gain further insight on the selection process and how it could be used to study the 
biological function of a target protein, as well as provide useful tools that do more than just bind, 
we turned our focus to the DXO protein, which has 5’-3’ exoribonuclease and is implicated in 
RNA surveillance.[6,7] To identify short RNA motifs that are enriched in DXO candidate aptamers, 
we subjected the random regions of the top 3,000 most abundant aptamer clusters from the DXO 
R4C4 pool to MEME analysis.[15,16] This analysis led to identification of DXO Motif 1 (5’-
GGATCCC-3’), which showed significant enrichment (E-value: 2.3e-7,360), was present on 
almost every candidate aptamer (2,932 out of 3,000), and showed high-specificity for DXO in that 
it was not identified in similar MEME analysis of other target pools (Figure 3.4a). The specificity 
of DXO aptamers containing this motif was also tested, and these aptamers showed no appreciable 
binding to non-specific targets (Appendix A, Figure A3). This motif is similar to the BamHI 
restriction site, which is included in the forward constant region of the N70 RNA library (see 
Materials and Methods). The motif is found to base-pair with the BamHI site in secondary structure 
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predictions giving rise to a stable stem structure close to the 5’-end of the RNA aptamer (Figure 
3.4b and Appendix A, Figure A4). We reasoned this may hinder the 5’-3’ exoribonuclease activity 
of DXO. We tested this hypothesis by incubating radiolabeled RNA aptamers (5 DXO candidate 
aptamers and the N70 RNA library) with DXO at 37°C in DXO exoribonuclease buffer, and 
monitoring the stability of full-length RNA via denaturing PAGE analysis. As shown in Figure 
3.4c, all five candidate DXO aptamers showed resistance against DXO exoribonuclease activity, 
with DXO #3, #4, and #5 showing the strongest resistance, when compared to the N70 RNA library 
control. Using a finer time-course for these tests, we estimated the half-lives of the DXO candidate 
aptamers to be ~1.5-3.5-fold higher (28.9-69.3 min) than that of the N70 library (19.8 min) 
(Appendix A, Figure A5). DXO has significantly lower exoribonuclease activity in SELEX buffer 
compared to DXO exoribonuclease buffer (data not shown), perhaps explaining why these 
aptamers were enriched and survived incubations with DXO for as long as 17 hours.  
To test whether the determining factor for RNA aptamer resistance against DXO 
exoribonuclease activity is the sequence of the motif itself or just the stability of the first stem in 
the aptamer structure, we took the DXO #2 and #5 aptamers with perfect matches to DXO Motif 
1, and generated mutant aptamers. In mut1 aptamers, the sequence of the motif was altered but the 
stability was maintained by changing the original motif (5’-GGATCCC-3’ to 5’-CCTAGGC-3’) 
and the BamHI site in the forward constant region (5’-GGATCC-3’ to 5’-CCTAGG-3’). In mut2 
aptamers, the stability of the first stem was reduced by changing the original motif to 5’-
AATATTC-3’ and the BamHI site in the forward constant region to 5’-AATATT-3’. In addition, 
we generated truncations of DXO #2 and #5 aptamers, which retained the DXO Motif 1 and the 
first stem-loop structure for each aptamer. A sequence-shuffled version of DXO #5 trunc was used 
as a control. As shown in Appendix A, Figure A6, these mutant and truncated aptamers are 
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predicted to adopt very similar, if not identical, secondary structures to the original aptamers. In 
the DXO exoribonuclease assay, the mut1 and truncated aptamers showed nearly identical 
stabilities compared to the original full-length RNA aptamers, whereas the mut2 aptamers showed 
enhanced susceptibility to degradation by DXO, similarly to that of the N70 aptamer library and 
DXO #5 shuffle control (Appendix A, Figure A6). These results highlight the importance of an 
RNA molecule’s 5’-end stability in determining its susceptibility to DXO-mediated degradation, 
which sheds light on the in vivo function of DXO and can help to identify in vivo targets of DXO 
exoribonuclease activity.  
Finally, we tested whether these RNA aptamers could inhibit the exoribonuclease activity 
of DXO. We measured the exoribonuclease activity on a 30-nt RNA substrate that was 3’-Cy5 
labeled. DXO was pre-incubated with a range of concentrations (0-1100 nM) of full-length RNA 
aptamers, and the RNA substrate was subsequently added. As shown in Figure 3.4d, even in the 
presence of 1.1 µM N70 RNA library, the Cy5-labeled substrate was almost completely degraded. 
Conversely, a substantial amount of RNA substrate was still intact after 2 hours of incubation with 
1 µM DXO in the presence of 730 nM DXO #2, 330 nM DXO #4, and 490 nM DXO #5 aptamer. 
By fitting these data to a dose-response curve, we calculated >>1100 nM, ~610 nM, ~290 nM, and 
~570 nM IC50 values for the N70 RNA library, DXO #2, DXO #4, and DXO #5 aptamers, 
respectively (Appendix A, Figure A7). In these samples, we have verified equal loading of 
different aptamers and the library, and they remained largely intact (Appendix A, Figure A7). 
Truncated versions of DXO #2 and #5 aptamers did not inhibit DXO exoribonuclease activity 
(Appendix A, Figure A8). These results suggest that the full-length DXO aptamers, but not the 
truncated versions, inhibit the exoribonuclease activity directly, not simply by competing off the 
RNA substrate.  
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Given their moderately-high affinity and DXO exoribonuclease inhibitory effect, these 
full-length aptamers could potentially be used as DXO inhibitors for studying DXO function in 
vivo. In the absence of a highly specific small molecule inhibitor of DXO, DXO-specific inhibitory 
RNA aptamers, which can in principle be expressed transgenically at specified levels, time points, 
and durations,[23,24] enable the functional study of DXO exoribonuclease activity in vivo. Likewise, 
compared to RNAi knockdowns, inhibitory RNA aptamers offer unique advantages for the 
following in vivo functional studies: i) a specific function or interaction of the target protein (e.g. 
exoribonuclease activity of DXO) could be targeted rather than complete elimination of the entire 
protein as with RNAi, and ii) distinction between primary and secondary effects is possible, since 
inhibitory concentrations of RNA aptamers could be attained relatively quickly (i.e. minutes to 
tens of minutes) upon induction, whereas significant knockdown of most proteins by RNAi 
requires hours to days. 
These studies have shown that different properties of the target proteins can also be 
discovered and studied through an aptamer selection. Furthermore, selecting sequences for more 
than just affinity, such as nuclease resistance and inhibition, can be accomplished. Some of the 
targets in this selection possess nuclease activity, which affected the affinity testing, and likely the 
selection process itself, as sequences with a higher resistance to the nuclease activity would be 
selected over those that may have higher affinity. DXO possesses 5’-3’ exoribonuclease activity, 
and we have shown that the selected aptamers resist degradation significantly longer than the 
random RNA library (Figures 3.4a and 3.4b). We also demonstrated that this resistance is due to 
the physical structure of the aptamer with a stem loop at the 5’ end. This type of structure was also 
shown to inhibit the exoribonuclease activity against an RNA substrate meant to represent nascent 
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RNA (Figure 3.4c). These results demonstrate an additional benefit and application of the SELEX 
process. 
 
Figure 3.4: Characterization of DXO aptamers. (a) A highly specific DXO motif identified by 
MEME[15,16] among the top 3,000 most abundant DXO aptamer clusters from R4C4. The E-value, 
representing the statistical significance of the identified motif as calculated by the MEME suite 
(http://meme-suite.org/), and number of aptamer clusters containing a match to Motif 1 are 
indicated. E-values lower than 0.05 are considered significant. (b) Secondary structure of DXO #2 
aptamer, a representative aptamer of the second highest multiplicity cluster for DXO from the 
R4C4 pool, as predicted by the mFold Web Server (http://unafold.rna.albany.edu/?q=mfold/RNA-
Folding-Form). DXO Motif 1 is colored cyan. Predicted secondary structures of other DXO 
aptamers are provided in Supplementary Fig. S3. (c) Stability of RNA aptamers against DXO 
exoribonuclease activity. Radiolabeled specific RNA aptamers or the N70 RNA library were 
incubated with DXO enzyme at 37°C for the indicated times and separated using 8% denaturing 
PAGE. Full-length RNA aptamers are indicated by . (d) Inhibition of DXO exoribonuclease 
activity by RNA aptamers. Degradation of a 3’-Cy5-labeled 30-nt RNA substrate by DXO in the 
absence and presence of indicated amounts of RNA aptamers as determined by 10% denaturing 
PAGE analysis. Full-length, intact RNA substrate and degradation product are indicated by  
and , respectively. The band indicated by * above the full-length RNA is likely incompletely 
deprotected RNA substrate (2’-ACE protected, Dharmacon). 
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4 Conclusions 
We have demonstrated that a highly multiplexed aptamer selection can be performed using 
the MEDUSA device, and its reconfigurable microcolumn design allows for substantial reduction 
in reagent consumption. Most notably, a single aliquot of the starting random library can be used 
to select aptamers to multiple different targets, and just 6µg of protein target is needed for each 
cycle. Additionally, a modified SELEX process incorporating increasing numbers of consecutive 
non-amplification cycles significantly reduced the time required to perform the selections. Most 
importantly, high-throughput aptamer selections are particularly beneficial because they increase 
the rate of success per selection.  
High-throughput sequencing allows for the identification of top sequences, as well as their 
multiplicity in the pool. Performing multiplex aptamer selections is also beneficial when analyzing 
sequencing results, since background binding and non-specific sequences can be recognized when 
they appear in multiple pools with significant abundance. However, after identifying potential 
aptamer candidates and performing binding experiments, it was obvious that sequence multiplicity 
could not predict binding or the affinity of the aptamer. 
Finally, through these selections, we demonstrated that useful tools, other than high-affinity 
ligands, can be discovered. Aspects of a target protein’s function were studied, and aptamers 
capable of resisting exoribonuclease activity and acting as inhibitors were determined. Therefore, 
aptamer selections can produce very useful tools that can be used in many different applications, 
and the device and selection process presented here provides advantages over other processes that 
improve the efficiency and success of aptamer selections. 
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CHAPTER 4 
MICROFLUIDIC DEVICE FOR APTAMER-BASED CANCER CELL CAPTURE AND 
GENETIC MUTATION DETECTION 
1  Introduction 
Cancer cells contain genetic mutations that allow them to escape the regulatory processes 
necessary for the healthy function of tissues and organs.[1-3] Moreover, there are numerous 
mechanisms for malignancy each with different combinations of genetic mutations, and cancer 
cells are constantly evolving,[4] which makes cancer treatment difficult with varying levels of 
efficacy. Therefore, developing an assay that can identify a cancer patient’s genetic mutations 
would provide a platform for more specific and detailed diagnoses, which would allow clinicians 
to better prescribe the most effective treatment strategy.  
Many assays have been developed that detect specific mutations, while other methods have 
been developed that detect all mutations via sequencing.[5-10] Each of these approaches has 
advantages and disadvantages.[8] However, most of these assays also require significant sample 
preparation performed in a bulk solution where the initial amount of genetic material is limited, 
some is lost in processing, and the remaining material is used up quickly. Therefore, an assay that 
incorporates sample preparation and can perform several types of analysis on the same small 
population of cells would be highly advantageous. 
To incorporate sample preparation into a cancer diagnostic, the first step is to selectively 
filter out cancer cells from a sample. Assays and devices are being developed that capture and 
isolate circulating tumor cells (CTCs), and although antibodies are traditionally used, aptamer-
based CTC capture is also being performed.[11-16] Aptamers have been used over antibodies in these 
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types of applications because of their increased robustness and ease of functionalization and 
oriented immobilization. With the advancement of cell-SELEX, aptamers to cell surface species 
in their native state will continue to be discovered. This will further progress the use of aptamers 
in cell capture devices, and due to their reproducible and relatively inexpensive synthesis, aptamer-
based diagnostic devices provide significant reliability and cost advantages over antibody-based 
systems. 
One approach to enabling multiple genetic analyses to be performed on a single small 
population of cells is to retain the original genomic template between processes. We previously 
developed a device for extracting and purifying human chromosomal DNA from lysed cells.[17] 
This device incorporated a fine micropillar array that captured megabase-long genomic DNA 
(gDNA) strands via physical entanglement. The physical nature of this isolation enables the gDNA 
to be isolated without dependence on biochemical or electrostatic forces, making it available for 
any downstream reactions. This also allows the gDNA to remain on the micropillar array during 
flow, which allows multiple downstream analyses to be performed within the microdevice. 
Here, we have designed and developed a device that incorporates both cancer cell capture 
and gDNA isolation and retention. With the gDNA isolated, specific genes are amplified for 
sequencing to determine any genetic mutations in those genes. The cancer cells are captured using 
aptamers immobilized on the microchannel surface, and the gDNA is isolated via physical 
entanglement within a micropillar array. In addition, we developed a modified version of multiple 
displacement amplification (MDA), an isothermal amplification technique, that amplifies a 
specific gene of interest. This amplification product undergoes sequencing, and the resulting 
sequence is compared to the known human genome to determine the presence of any genetic 
mutations. We have used our device to capture HeLa and CAOV-3 cancer cells using aptamers, as 
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well as subsequent isolation of their gDNA. We have also demonstrated on-chip amplification of 
the TP53 gene, which is a gene of interest in cancer, from HeLa and CAOV-3 cells and sequenced 
a fragment of this gene for genetic mutation detection. We were able to identify the presence of a 
point mutation in the CAOV-3 TP53 gene. This technology enables the identification of specific 
key mutations in a timely and cost-effective manner. Using this device to provide a more detailed 
diagnosis for each cancer patient would allow clinicians to better prescribe the most effective 
treatment options. Furthermore, since cancer cells are constantly evolving, regular testing of 
multiple important genes is beneficial for monitoring disease progression and determining future 
treatment, which could also be accomplished using our device.  
2 Materials and Methods 
 
2.1 Cell Culture and Buffers 
HeLa and CAOV-3 cells were purchased from American Type Cell Culture (ATCC). Both 
cell lines were cultured in DMEM media (Life Technologies) supplemented with non-essential 
amino acids, 110 mg/L sodium pyruvate, 200mM L-glutamine (Life Technologies), 1x Pen Strep 
(Life Technologies), 26.8 mM HEPES, betamercaptoethanol, and containing 10% fetal bovine 
serum. Prior to use, the cells were trypsinized and resuspended in phosphate-buffered saline (PBS) 
binding buffer [1x Dulbecco’s PBS with calcium chloride and magnesium chloride (Fisher 
Scientific) containing 4.5 g/L glucose and 5 mM MgCl2]. HeLa cells contained GFP-conjugated 
histones and CAOV-3 cells were stained with calcein-AM (Thermo Fisher Scientific) that allowed 
them to be observed using fluorescence microscopy.  
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2.2 Device Fabrication 
The devices used here were polydimethylsiloxane (PDMS) microchannels bonded to glass 
substrates. The devices consisted of two orthogonal microchannels that contained two micropillar 
arrays: a cell capture array at the intersection of the two microchannels and a gDNA isolation array 
downstream of the cell capture array (see Figure 4.1). The PDMS channels were made via soft 
lithography using a silicon master mold. The master mold was fabricated from a 4” silicon wafer 
via standard photolithography. Microposit S1813 photoresist (Shipley) was spun on silicon wafers 
and exposed to UV light using a contact mask aligner (ABM). The exposed wafer was developed 
using 726MIF developer (Microchemicals) and the pattern was etched 25 µm into the silicon via 
Bosch process using a Unaxis SLR 770 deep reactive ion etching system (Unaxis USA Inc.). A 
monolayer of (1H,1H,2H,2H-Perfluorooctyl)Trichlorosilane (FOTS) was deposited onto the 
etched silicon surface using an MVD100 molecular vapor deposition system (Applied 
Microstructures) to enable easy release of the PDMS from the silicon mold.  
Sylgard 184 (Dow Corning) PDMS base resin was mixed at a 10:1 ratio with curing agent, 
and degassed in a vacuum oven at room temperature. The PDMS was poured onto the master mold 
and baked at 140°C for 1 hour. The PDMS was allowed to cool to room temperature, and it was 
carefully peeled off of the mold. Inlet and outlet holes were created using a 1.5mm biopsy punch 
(Sklar Instruments). To complete the formation of the channels, the patterned PDMS and a 
microscope slide were treated with oxygen plasma for 5 min, and then bonded together. An 
external 4-way L-type valve (IDEX Health and Science) was used at the DNA channel inlet and 
external 2-way valves were used at the cell channel inlet and both outlets to control the flow 
between the perpendicular channels. 
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2.3 Surface Chemistry 
DNA aptamers that were used to capture cancer cells were immobilized onto the surface of 
the microchannels via a streptavidin-biotin conjugation. The channels were initially primed and 
cleaned with ethanol and ultrapure water. A 1x PBS solution was flowed through the channels at 
50 µL/min for 9 min. A 1 mg/mL solution of streptavidin (Life Technologies) in PBS was 
prepared, and 120 µL were pumped through the cell channel (see Figure 4.1) at 4 µL/min to 
immobilize streptavidin via adsorption to the channel surface. A 1% bovine serum albumin (BSA) 
solution was prepared in PBS binding buffer, and 500 µL of this solution was pumped through 
both the cell and DNA channels at 4 µL/min to block the surface of the channel and prevent non-
specific adhesion of cells and other reagents. Finally, biotinylated aptamers (Integrated DNA 
Technologies), which were previously selected to bind to several different types of cancer cells,[18] 
were diluted to 10 µM in PBS binding buffer, and 180 µL were pumped through the DNA channel 
at 3 µL/min. This process enabled the aptamers to be concentrated in the cell capture region at the 
intersection of the two channels. 
2.4 Cell Capture, Lysis, and gDNA Isolation 
Cells suspended in PBS binding buffer were pumped through the cell channel (see Figure 
4.1) at 1 µL/min until several cells were captured, as observed via fluorescence microscopy. A 
solution of 6 M guanidinium isothiocyanate was pumped at 1 µL/min through the DNA channel 
until cell lysis was observed. By lysing the cells in the direction of the DNA micropillar array, the 
gDNA becomes physically entangled and remains in the channel even under flow. To verify the 
gDNA was captured by the micropillar array, YOYO-1 dye was used to stain the DNA in the 
channel by flowing it through the DNA channel at 1 µL/min. Otherwise, following lysis, the gDNA 
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was washed with 1x TE buffer to remove any remaining cellular debris and guanidinium 
isothiocyanate. 
2.5 Primers and Specific Gene Amplification from gDNA 
To amplify a specific gene from gDNA isothermally, MDA was used with specific primers 
targeting a fragment of the TP53 gene. Table 4.1 contains the 40 short primers used for this 
amplification. Initially, the isolated gDNA was chemically denatured using Buffer DLB from the 
Repli-g Mini Kit (Qiagen) prepared according to the manufacturer’s instructions. This solution 
was pumped through the DNA channel at 1 µL/min for 25 min. The gDNA was then neutralized 
using the Stop Solution from the Repli-g Mini Kit with the addition of 12 pmol of each MDA 
primer. This solution was pumped at 1 µL/min for 25 min. An MDA reaction solution was prepared 
from the Repli-g Mitochondrial DNA Kit according to the manufacturer’s instructions, and 30 
pmol of each MDA primer was added to the reaction solution. The microchannel device was placed 
on a hotplate set to 31°C, and 50 µL of MDA reaction solution was pumped through at 0.05 µL/min 
to perform the MDA reaction for approximately 16 hours. The eluent was collected in an 
Eppendorf tube. For benchtop control experiments, gDNA from HeLa cells was extracted using 
the Blood and Cell Culture DNA Mini Kit (Qiagen). Buffer D1 and Buffer N1 from the Repli-g 
Mini Kit (Qiagen) were prepared, and 15 ng of extracted gDNA were denatured and neutralized 
according to the manufacturer’s instructions. An MDA reaction master mix was prepared using 
the buffer and DNA polymerase from the Repli-g Mitochondrial DNA Kit (Qiagen) and various 
concentrations of specific MDA primers (Table 4.1), and this solution was added to the denatured 
gDNA. This reaction was incubated at 31°C for 16 hours. 
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Table 4.1: Amplification Primer Sequences 
MDA Primers for the TP53 Gene 
Primer Name Sequence Primer Name Sequence 
TP53 MDA FOR #1 TTG TGC CCT G TP53 MDA REV #1 GCC ATG GCG C 
TP53 MDA FOR #2 CAG TTG CTT T TP53 MDA REV #2 GCT GTG ACT G 
TP53 MDA FOR #3 GTT TCT TTG C TP53 MDA REV #3 CCT CAC AAC C 
TP53 MDA FOR #4 GGA GGT GCT T TP53 MDA REV #4 CGC TCA TGG T 
 TP53 MDA FOR #5 TAG CTC GCT A TP53 MDA REV #5 CAC CAT CGC T 
TP53 MDA FOR #6 GTG TAG ACG C TP53 MDA REV #6 TCT CTC CAG C 
TP53 MDA FOR #7 CCT ATC TCA A TP53 MDA REV #7 CTG GGC AAC C 
TP53 MDA FOR #8 CCT GAG TGA C TP53 MDA REV #8 GAA TCA GAG G 
TP53 MDA FOR #9 ATC ACA CCA C TP53 MDA REV #9 ACC TAA GAG C 
TP53 MDA FOR #10 GGA GGC TGC A TP53 MDA REV #10 AGA TGC TGA G 
TP53 MDA FOR #11 ATC ACT TGA G TP53 MDA REV #11 TCC ACA CGC A 
TP53 MDA FOR #12 TAG GAG GCT G TP53 MDA REV #12 TGT TTC TGT C 
TP53 MDA FOR #13 CAC CTA TAG T TP53 MDA REV #13 CAC CAC ACT A 
TP53 MDA FOR #14 TAG CCA GGC A TP53 MDA REV #14 TCA GGC GGC T 
TP53 MDA FOR #15 ACC TCG TCT C TP53 MDA REV #15 CCC CAG TTG C 
TP53 MDA FOR #16 AGC CTG GGT A TP53 MDA REV #16 TTA ACC CCT C 
TP53 MDA FOR #17 GAG CCC AGG A TP53 MDA REV #17 AGG GCC ACT G 
TP53 MDA FOR #18 CCA AGG CAG G TP53 MDA REV #18 CCC CCC TAC T 
TP53 MDA FOR #19 TCC CAG CAC T TP53 MDA REV #19 TAG GGA GGT C 
TP53 MDA FOR #20 TTG GTG GCT C TP53 MDA REV #20 TTG CAC ATC T 
PCR Primers 
Primer Name Sequence 
TP53 PCR FOR ACT TTC AAC TCT GTC TCC TTC CTC TTC CTA 
TP53 PCR REV GGA CGC GGG TGC CG 
 
2.6 Gene Sequencing 
The MDA product was verified by running the product on a 1% agarose gel, and staining 
the gel with SYBR gold (Thermo Fisher Scientific). Since the product was around 10 kilobases 
(kb), a smaller product must be made to enable sequencing. Thus, a PCR amplification was 
performed using 10-50% of the MDA product. The PCR product was verified and purified using 
8% PAGE stained with ethidium bromide. To purify the PCR product for sequencing, the 130-nt 
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band was cut from the gel, crushed, suspended in 3 M NaAc pH 6.2, and incubated at 37°C with 
mixing overnight. The gel pieces were removed from the sample, the sample underwent phenol-
chloroform extraction and ethanol precipitation, and the DNA was resuspended in DEPC water. 
This purified PCR product was sequenced via Sanger Sequencing, and the sequence was compared 
to the known wildtype gene. 
3 Results and Discussion 
3.1 Microchannel Design 
The assay presented here involves two main steps, cancer cell capture using aptamers and 
genomic DNA analysis. The ability to perform these two steps easily all within one device would 
significantly reduce contamination and sample loss, which is important when developing an assay 
for rare cells. Therefore, the device was designed to have two intersecting orthogonal 
microchannels: the cell channel where cancer cells are captured, and the DNA channel where the 
gDNA from the captured cells is isolated (Figure 4.1). The cell channel was 1 mm wide, and the 
DNA channel was 250 µm, 500 µm, or 1 mm wide. The depth of the channels was ~25 µm. The 
device also contained two micropillar arrays, one for cancer cell capture and one for gDNA 
isolation. The cell capture array was located at the intersection of the two microchannels, and 
consisted of pillars 50 µm in diameter. This array was rotated by 4° to maximize the contact 
between the cells and the channel surface containing the aptamers, thereby improving the capture 
efficiency.[19] The DNA micropillar array was very similar to our previously-developed microarray 
for gDNA isolation.[17] The array presented here consisted of 4x4 µm pillars spaced in a gradient 
that started with the pillars 10 µm apart and finished with them 7 µm apart. These small pillars 
placed in such a fine array caused the gDNA to become physically entangled and remain on the 
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array even under flow, while allowing the cellular debris to flow out of the device. This is highly 
advantageous and enables multiple type of analysis to be performed on the same gDNA template.  
 
Figure 4.1: Microchannel design for capturing cancer cells and isolating their gDNA. The device 
contains two orthogonal channels, the cell channel and the DNA channel. It also contains two 
micropillar arrays, the cell capture array located at the intersection of the channels (red box, scale 
bar: 200 µm) and the DNA isolation array located downstream of the cell capture array in the DNA 
channel (blue box, scale bar: 30 µm). 
 
To control the flow within the device, valves were needed at the inlets and outlets. An 
external 4-way L-type valve was used at the DNA channel inlet to not only control flow, but also 
eliminate most of the dead volume caused by the length of tubing needed to reach the syringe 
pump while the device is either observed under a microscope or is incubated using a hotplate. This 
is necessary because high initial flowrates cannot be used after the gDNA is isolated on the 
micropillar array, as there is a risk of losing some of the entangled gDNA under the high flow 
conditions. External 2-way shutoff valves were used at each of the outlets as well as the cell 
channel inlet to control the fluid flow. These types of valves were used because they do not disturb 
the fluid within the channels, whereas controlling the flow using tubing clamps causes significant 
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flow during the clamping process, which can disturb the captured cells and gDNA. This device 
design and setup enables this assay to be performed easily by the user. 
3.2 HeLa and CAOV-3 Cell Capture and Genomic DNA Isolation 
The target cells were suspended in PBS binding buffer and pumped through the device with 
aptamers immobilized on the surface of the cell capture region containing a pillar array. The cell 
capture was most efficient at a flowrate of 1 µL/min when the cells were freshly trypsinized and 
the channel depth was ~25 µm. Several flowrates were tested ranging from 20 µL/min down to 0.1 
µL/min. At high flowrates (>5 µL/min), the linear velocity of the cells was very high and the cells 
did not bind to the aptamers on the surface easily. At low flowrates (<1 µL/min), the cells did bind 
to the aptamers, but the throughput was very low and there was increased non-specific adhesion 
of the cells to the device. Cells used from frozen stocks did not bind as readily, likely due to 
different surface compositions caused by the shock of a freeze/thaw cycle. With channels deeper 
Figure 4.2: Cancer cell capture in microfluidic channels using aptamers. (a) Brightfield and 
fluorescent images of the cell capture region without aptamers after flowing HeLa cells through 
the microchannels. (b) Brightfield and fluorescent images of the cell capture region containing 
aptamers after flowing HeLa cells through the microchannels. The blue circles highlight the 
captured cells. (c) Brightfield and fluorescent images of the cell capture region without aptamers 
after flowing CAOV-3 cells through the microchannels. (d) Brightfield and fluorescent images of 
the cell capture region containing aptamers after flowing CAOV-3 cells through the 
microchannels. The HeLa cells fluoresce due to GFP bound to their histones, and the CAOV-3 
cells were stained with calcein-AM. 
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than 25 µm, the cell capture took longer, since fewer collisions with the channel surface were 
likely occurring. To demonstrate using aptamers to capture cancer cells within the microchannels, 
cells were pumped through channels with and without aptamers immobilized on the surface. Figure 
4.2a and 4.2b show the cell capture region without aptamers (Figure 4.2a) and with aptamers 
(Figure 4.2b) after HeLa cells were pumped through the channel. Figure 4.2c and 4.2d show the 
results from the same experiment performed using CAOV-3 cells. These results demonstrate the 
use of aptamers to successfully capture cancer cells. 
After successfully capturing cancer cells within the cell capture region, the cells were lysed 
through the DNA channel. The cell contents flowed through the DNA micropillar array, and the 
gDNA was isolated on the pillars via physical entanglement. To verify that the gDNA was isolated 
and retained within the micropillar array, the gDNA was stained with YOYO-1 dye, and the results 
are shown in Figure 4.3 for both HeLa and CAOV-3 cells. The gDNA from both types of cells was 
Figure 4.3: Cancer cell lysis and isolation of gDNA via physical entanglement within the 
micropillar array. (a) Brightfield and fluorescent images of HeLa cells bound to aptamers in the 
cell capture region. (b) Fluorescent image of gDNA from HeLa cells isolated by the micropillar 
array and stained with YOYO-1 dye. (c) Brightfield and fluorescent images of CAOV-3 cells 
bound to aptamers in the cell capture region. (b) Fluorescent image of gDNA from CAOV-3 cells 
isolated by the micropillar array and stained with YOYO-1 dye. 
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successfully isolated by the micropillar array and remained within the microchannel after multiple 
hours of flow. This gDNA isolation technique has several advantages, including allowing the 
gDNA to be completely chemically available for any downstream reaction, and more importantly 
it enables the gDNA to be retained within the device even under flow. This enables multiple types 
of analyses to be performed on the same template gDNA, so a large amount of information can be 
gathered from a single small population of cells without necessitating substantial whole genome 
amplification, which can be biased and information can be lost.[20-22] 
3.3 Specific Isothermal Amplification of the TP53 Gene from gDNA 
With the gDNA isolated and retained within the micropillar array, several types of genetic 
analyses can be performed. Here, we demonstrated the amplification of a specific gene to 
determine its nucleotide sequence and discover any genetic mutations. MDA, an isothermal 
amplification technique, was used to reduce the complexity and cost of the device and enable 
straightforward device operation, since thermocycling is not necessary. MDA uses many short 
primers and a strand-displacing DNA polymerase (φ29) to make numerous copies of the template 
DNA. Whereas MDA is commonly used as a method for whole genome amplification,[23-26] in this 
work we use MDA to amplify a specific gene from gDNA. To our knowledge, this is the first 
demonstration of using MDA to amplify a specific gene from gDNA. Forty 10-nt primers (20 
forward and 20 reverse primers) were designed around a region of the TP53 gene, which is a 
commonly mutated gene in cancer whose resulting protein (p53) is responsible for monitoring 
genetic integrity and preventing cell survival and proliferation in the presence of genetic 
damage.[27] This modified MDA technique for amplifying the TP53 gene from gDNA was initially 
verified in benchtop experiments using purified HeLa gDNA. Figure 4.4a shows the successful 
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amplification of TP53 from purified gDNA. Shorter gene fragments were also produced via PCR 
from these MDA products (Figure 4.4b). 
 
Figure 4.4: Gel images of benchtop demonstration of specific MDA of the TP53 gene and smaller 
gene fragment from PCR. (a) MDA product from reactions using 15 ng of purified gDNA. 
Different quantities of primers were tested, as well as negative controls containing no gDNA 
template. The MDA product was approximately 10 kb. (b) PCR product from reactions amplifying 
a shorter TP53 gene fragment using 60% of the MDA product. The PCR product is 130 nt in 
length. 
 
The isolated gDNA from HeLa and CAOV-3 cells was first chemically denatured to create 
single stranded DNA (ssDNA). The DNA was then neutralized prior to the MDA reaction. Since 
the gDNA is entangled in the micropillar array, upon denaturation the two complimentary strands 
likely cannot diffuse and migrate away from each other as readily as they can in a bulk solution, 
so it is possible that some may rehybridized upon neutralization. This would prevent the MDA 
reaction from occurring efficiently. To reduce the likelihood of this occurring, the neutralization 
buffer was spiked with the MDA primers allowing the primers to bind to the ssDNA before it 
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rehybridizes. The MDA reaction solution containing additional primers and the DNA polymerase 
was pumped through the device and the amplification product was collected. The MDA product 
from HeLa and CAOV-3 cell gDNA was analyzed on an agarose gel, and Figure 4.5a shows 
images of the gels after a successful MDA reaction. The MDA product DNA strands were around 
10 kb in length, and this is because the φ29 polymerase is known to extend for approximately 10 
kb.[28,29] To prepare the amplified gene sample for sequencing, it must be shortened to 
accommodate the sequencing technology. For Sanger sequencing, up to a few hundred bases can 
be sequenced. To create a shorter gene fragment from the HeLa and CAOV-3 MDA product, PCR 
was used to create 130-nt DNA strands, which were verified via PAGE (Figure 4.5b). MDA is an 
advantageous technique to use not only because it is isothermal, but also because amplifying 10-
kb strands allows whole genes to be amplified from the gDNA template. These genes can be 
Figure 4.5: Gel images after running MDA and PCR products. (a) On-chip MDA product from 
isolated HeLa and CAOV-3 cell gDNA verified using a 1% agarose gel. The ladder indicates that 
the product is around 10 kb in length. (b) PCR product verified via 8% PAGE. The ladder 
confirmed a product length of 130 bp. 
 100 
 
completely sequenced inexpensively by performing a few PCRs to isolate different regions of the 
gene, and performing Sanger sequencing on these pure samples. Alternatively, the MDA product 
can be digested into shorter fragments and targeted next-generation sequencing can be performed. 
3.4 Sequencing of the TP53 Gene Fragment 
The purified TP53 gene fragment from HeLa and CAOV-3 cells was sequenced via Sanger 
sequencing. This sequencing technique was chosen because it is fast, inexpensive, and can perform 
longer reads than other techniques. It also requires the sample to be pure, as only one read is 
performed. The sequencing results from the TP53 gene fragments from both HeLa and CAOV-3 
cells are shown in Figure 4.6. The wildtype sequence for TP53 was obtained from the International 
Agency for Research on Cancer, and the wildtype nucleotide sequence for the short fragment tested 
here is shown in Figure 4.6. From these results, we were able to detect a point mutation in the 
CAOV-3 TP53 gene, while HeLa cells contained the wildtype sequence of this gene fragment. 
This confirms that CAOV-3 cells contain a nonsense mutation in the TP53 gene leading to an 
Figure 4.6: Sanger sequencing results from HeLa and CAOV-3 cell TP53 gene fragments. The 
wildtype sequence for this fragment is shown at the top of the figure and was obtained from the 
International Agency for Research on Cancer. Plots from sequencing runs for both HeLa and 
CAOV-3 TP53 gene fragments are shown with the corresponding bases indicated. The highlighted 
bases indicate the location of the known point mutation in CAOV-3 cells, and the specific base 
that is mutated is underlined. There are some bases that were not called, but the sequence can be 
discerned by looking at the peaks. 
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aberrantly-functioning p53 protein. Analogous testing of all locations on this gene would allow us 
to determine additional genetic information about this gene in these two cancer cell lines. 
Additional genes that commonly contain mutations in cancer could also be tested in this way, since 
the gDNA is retained on the micropillars and is available for additional amplification reactions 
and analysis. 
4 Conclusions 
We have developed a device and technique for capturing cancer cells using aptamers, and 
isolating their gDNA for genetic analysis. The device was designed to enable both the cell capture 
and gDNA isolation to occur within a single device to significantly reduce contamination and 
sample loss. Preventing sample loss is particularly important, since most cells of interest, such as 
circulating tumor cells, are rare and are generally found in low numbers. The device was also 
designed to isolate the gDNA via physical entanglement within a micropillar array. This isolation 
technique allows the gDNA to be chemically available for downstream reactions. It also enables 
the gDNA to be retained within the microchannel even under flow, which enables multiple types 
of analyses to be performed on the same template gDNA.  
We demonstrated on-chip isothermal amplification of a specific gene and subsequent 
sequencing of this gene to determine any genetic mutations. We successfully detected a point 
mutation in the TP53 gene in CAOV-3 cells.  Specifically, we developed a method using MDA to 
amplify a specific gene from whole gDNA. This technique allows for long strands of DNA to be 
produced that can cover an entire large gene up to 10 kb. Here, we used PCR to produce pure 
samples of smaller gene fragments that could be sequenced using Sanger sequencing, but other 
sequencing methods can be used where pure samples are not necessary as multiple reads are taken. 
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An assay like this can be extremely impactful when it comes to cancer diagnosis and 
treatment. If the mutations present in a specific patient’s cancer cells can be identified, clinicians 
will be able to use this information to better diagnose the patient and better determine the most 
effective treatment options. This would truly enable precision medicine when it comes to cancer 
treatment, which is necessary to effectively treat patients considering the substantial diversity 
observed in cancer.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
Aptamers have the potential to rival antibodies as the affinity ligand of choice in many 
applications, including biosensors and diagnostics, imaging, and therapeutics. They are capable of 
binding to their targets with the same strength and specificity, but provide several benefits over 
antibodies.[1] However, despite the past 26 years of aptamer research, antibodies are still the gold 
standard. One of the main reasons for this is the difficulty in selecting aptamers to new targets. 
The aptamer selection process is very time consuming and expensive, and the majority of 
selections are unsuccessful in discovering an aptamer that binds with high affinity and specificity. 
I believe that this is the most important hurdle to overcome before aptamers will be used regularly. 
To contribute to the effort of improving aptamer discovery, we developed a Microplate-based 
Enrichment Device Used for the Selection of Aptamers (MEDUSA). This device is a scaled-up 
version of our microcolumn technology in which 96 microcolumns are contained within one device 
with the same dimensions as a 96-well microplate. This allows MEDUSA to directly couple to a 
96-well plate to facilitate high-throughput downstream processes. MEDUSA is also very versatile 
in that it can be reconfigured in many ways between microcolumns in parallel and microcolumns 
connected in series. As we have demonstrated, MEDUSA can not only perform high-throughput 
parallelized selections, but can also be used to characterize and optimize aptamer selection 
processes, so improved, more efficient selection techniques can be developed that greatly increase 
success rates resulting in the increased production of high affinity aptamers. Another important 
feature of this device is that its microplate-based design lends itself to process automation using 
existing liquid-handling robots that are compatible with 96-well microplates. This would further 
improve the efficiency and throughput of aptamer selections. Establishing technologies that 
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provide rapid and reliable methods for high-throughput aptamer discovery would advance the 
aptamer field and promote the widespread use of aptamers. 
Equally important to efficient aptamer discovery is the development of applications that use 
aptamers to improve upon existing technologies. Therefore, we have also worked toward creating 
novel assays that incorporate aptamers. We have shown that MEDUSA’s versatility enables it to 
be used for more than just aptamer selections. We demonstrated sample preparation techniques in 
the microcolumns where dilute protein samples were purified and concentrated using aptamer-
immobilized resin. A step further would be to separate, purify, and concentrate several species 
from complex mixtures using MEDUSA by connecting several microcolumns in series, and again, 
these processes could be automated using existing systems that handle 96-well plates.  
One area of research that could greatly benefit from aptamer-based technologies is that of 
cancer. Cancer is a disease that has been extensively studied by researchers in an attempt to 
understand its underlying causes and mechanisms, and more importantly, to treat it effectively. 
However, despite many decades of research, it is still not well understood, and is still one of the 
leading causes of death in the world.[2] The specific characteristics of the disease often vary 
significantly between patients, and this is fundamentally due to the genetic variations present in 
the cancer cells that allow them to ultimately escape the regulatory processes necessary for the 
healthy function of tissues and organs.[3-5] There are numerous mechanisms for malignancy each 
with different combinations of genetic mutations and cancer cells are constantly evolving, which 
makes cancer treatment difficult with varying levels of efficacy. Therefore, improved cancer 
diagnostics would make a significant impact in how cancer patients are treated. More specifically, 
regular testing of patient’s cancerous cells to monitor their physical characteristics and genetic 
information would be quite beneficial. This would allow clinicians to use substantially more 
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information about the patient’s specific cancer cells to better prescribe the most effective treatment 
strategy. For this to be possible, the testing would need to be rapid and reasonably inexpensive.  
Toward these goals, we have developed a technology capable of capturing rare cancer cells 
from a complex sample, such as blood, and isolating their gDNA for analysis all within a single 
device. By combining these steps into a single device, the risk of contamination and sample loss 
are eliminated. To capture cancer cells, aptamers that bind specifically to cancer cells are 
immobilized within a microchannel containing a micropillar array to increase capture efficiency. 
The captured cells are lysed, and a secondary, finer micropillar array isolates the gDNA via 
physical entanglement. This technology provides a platform where different types of testing can 
be performed on the same population of cells. Initially, once the cells are captured, testing can be 
performed on whole cells to determine their surface composition. For example, fluorescent 
labeling and staining can be done to identify the presence and abundance of different surface 
species. The cells can then be lysed, their gDNA captured, and then several types of analysis can 
then be performed on the gDNA to gather information about the genetics of this specific population 
of cancer cells. We have demonstrated how genetic mutations in specific genes of interest can be 
identified through amplification of a specific gene and subsequent sequencing of that gene product. 
Since the gDNA is retained within the microchannel, several amplification reactions could be 
performed consecutively for different genes, or a larger amplification reaction targeting many 
cancer genes could be performed to prepare a sample for targeted next generation sequencing.[6-10] 
Different fluorescent techniques, such as fluorescence in situ hybridization (FISH),[11-14] could also 
be performed to analyze the cancer genetics. Furthermore, with the analysis occurring within a 
single device, these processes could be automated to increase the speed and efficiency of the 
testing. Therefore, with many different types of analysis possible, this technology can provide 
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clinicians with a plethora of information about each specific population of cancer cells, which 
helps them prescribe the most effective treatment strategies.  
Aptamers that bind to cancers cells are not only useful for diagnostic applications like our 
technology where they are used to capture and filter out cancer cells from complex mixtures 
containing several different types of cells, but these aptamers can also be used in biomarker 
discovery for early detection and cancer therapeutics. Aptamers that can bind specifically to 
cancer-related cell surface molecules can be used for delivering targeted drugs and precisely 
directed therapies. The process by which aptamers to cells are discovered is known as cell 
systematic evolution of ligand by exponential enrichment (Cell-SELEX).[15,16] This approach 
allows for specific ligands to be identified that bind to external biomarkers on cancer cells without 
requiring any prior knowledge about the cells.[17] Currently, the aptamer selection process to 
cellular targets is very time consuming and often does not result in a high-quality aptamer.[17-19] 
One seemingly universal problem is dead cell contamination causing nonspecific binding and 
resulting in aptamers with low specificity and limited affinity to the live target cells.[20-22] These 
limitations could potentially be overcome using our microcolumn technology for aptamer 
selections to cells, since it has been shown to reduce the number of selection rounds needed, and 
the dynamic flow ensures that non-adherent dead cells are expelled into waste. This technique 
could subsequently be scaled up and automated using MEDUSA. An optimal cell-SELEX 
technique would allow for the discovery of novel cancer cell-specific aptamers and cancer 
biomarkers more rapidly, giving rise to the possibility of targeted therapies customized for each 
patient, and with higher affinity, enabling earlier detection and diagnosis due to a lower detection 
limit. 
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Precision medicine, where diagnostics and therapeutics are catered to each individual 
patient, would revolutionize the healthcare industry, and greatly improve lives and life 
expectancies. I believe that aptamers could be key to achieving precision medicine. In order to 
bring the aptamer field forward toward these goals, technologies that improve the aptamer 
discovery process must continue to be developed. Establishing efficient and reliable methods for 
selecting specific high affinity aptamers to targets and cells associated with disease is paramount 
to developing diagnostics for early detection and targeted therapeutics. In addition, developing 
technologies and treatments that effectively use these aptamers is also very important. Therefore, 
I believe through continued research and collaboration in the aptamer, diagnostic, and therapeutic 
fields we have the potential to achieve truly personalized and precision medicine. 
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APPENDIX A 
SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 3 
Table A.1: Summary of sequencing results and clustering 
  Total # of reads Quality filtered (>Q25 for 80%) Percent passed quality filter: 
   
Lane1 210774447 132780375 63.00    
Lane2 205393613 68306006 33.26    
Sequencing 
Lane Target protein SELEX Round-Cycle Barcode Barcode matched 
Clustered 
Reads % Clustered 
Lane1 
Amylose 
R3C3 1 3751360 3090917 82.4 
R4C4 2 4275552 3860899 90.3 
GCN5_GNAT 
R2C2 3 3632234 3335381 91.8 
R3C2 4 3315571 2993167 90.3 
R3C3 5 3347685 3025012 90.4 
R4C2 6 3454226 3127458 90.5 
R4C3 7 4888895 4364730 89.3 
R4C4 8 4086807 3535763 86.5 
JMJD2_Clav 
R3C3 9 2444505 2246627 91.9 
R4C4 10 5013347 4200451 83.8 
MBP 
R2C1 11 2264022 2092324 92.4 
R2C2 12 4830747 4401192 91.1 
R3C2 13 4505792 4081211 90.6 
R3C3 14 4782592 4367501 91.3 
R4C2 15 4108004 3648420 88.8 
R4C3 16 3453035 3103763 89.9 
R4C4 17 2194247 1922155 87.6 
MOF_Chromo 
R3C3 18 3983548 3664643 92.0 
R4C4 19 4043852 3598491 89.0 
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TIP60_Chromo 
R2C1 20 4093407 3735109 91.2 
R2C2 21 3930809 3544290 90.2 
R3C2 22 3575983 3266581 91.3 
R3C3 23 2406272 1641927 68.2 
R4C2 24 3729753 3104503 83.2 
R4C3 25 3144953 2892011 92.0 
R4C4 26 4582331 4132911 90.2 
UTX_JMJC 
R3C3 27 5184360 4734991 91.3 
R4C4 28 3681639 3297236 89.6 
Unmatched     18190321     
 
Lane2 
AgRai1 
R3C3 1 2324032 2146812 92.4 
R4C4 2 84290 76828 91.1 
Ash1_BAH 
R3C3 3 2269338 2102474 92.6 
R4C4 4 1884865 1611908 85.5 
DXO 
R3C3 5 2211899 2040984 92.3 
R4C4 6 2090182 1951136 93.3 
FLAG-RTF1 
R3C3 7 2131522 1961767 92.0 
R4C4 8 1289219 1124605 87.2 
FLAG 
R3C3 9 2365489 2185911 92.4 
R4C4 10 2173980 1925590 88.6 
JMJD2_JMJC 
R3C3 11 2575224 2383706 92.6 
R4C4 12 1102417 983567 89.2 
NELF-E 
R2C1 13 2486073 2318500 93.3 
R2C2 14 2347505 2172774 92.6 
R3C2 15 1731767 1590004 91.8 
R3C3 16 1135320 1038583 91.5 
R4C2 17 2132048 1973489 92.6 
R4C4 18 2194432 2035697 92.8 
NiNTA 
R3C3 19 1584669 1432636 90.4 
R4C4 20 5926827 5306374 89.5 
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Trx_ZnF 
R3C3 21 3008680 2753132 91.5 
R4C4 22 2844793 2529447 88.9 
mutPNPase 
R3C3 23 1756627 1622867 92.4 
R4C4 24 1830710 1683166 91.9 
wtPNPase 
R3C3 25 481140 338727 70.4 
R4C4 26 919315 749263 81.5 
p23 
R3C3 27 2672349 2467321 92.3 
R4C4 28 2517795 2308017 91.7 
unmatched     7046111     
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Table A.2: Target Protein Information 
Protein 
Name 
GenBank ID Protein Function Specific Domain 
Domain 
Boundaries 
(a.acids - 
a.acids) 
Domain Function 
Molecular 
Weight 
(kDa) 
Isoelectric 
point (pI) 
Affinity 
Tag/Resin 
used for 
SELEX 
TIP60 NM_131923 
H4 and H2A histone acetyltrasnferase. 
Catalytic subunit of NuA4 HAT 
complex. 
Chromodomain 11-300 
Involved in protein-protein and/or 
protein-nucleic acid interactions. Many 
chromodomains act as methyl-specific 
histone binding module, and some 
chromodomains were found to 
associate with RNA.  
31.5 8.25 
MBP/ 
Amylose 
GCN5 AF029776 
A major histone acetyltransferase, which 
promotes transcriptional activation. 
Catalytic subunit of SAGA, SALSA, and 
ADA complexes. 
GNAT domain 481-627 
Gcn5-related N-acetyltransferases 
(GNAT) catalyze the transfer of the 
acetyl from the CoA donor to a 
primary amine of the acceptor. 
16.8 8.64 
MBP/ 
Amylose 
MOF NM_078496 
A major histone acetyltransferase, which 
promotes transcriptional activation. 
Catalytic subunit of MSL and NSL 
complexes. 
Chromodomain 376-539 
Involved in protein-protein and/or 
protein-nucleic acid interactions. Many 
chromodomains act as methyl-specific 
histone binding module, and some 
chromodomains were found to 
associate with RNA.  
18.7 7.00 
MBP/ 
Amylose 
UTX NM_135524 
Histone demethylase that specifically 
demethylates 'Lys-27' of histone H3. 
JMJC domain 832-995 
Catalytic domain responsible for 
histone demethylation. Predicted  
metalloenzyme domain with cupin fold 
that binds Fe(III) and alphaKG. 
18.7 7.15 
MBP/ 
Amylose 
JMJD2 NM_136487 
Histone demethylase that specifically 
demethylates 'Lys-9' and 'Lys-36' 
residues of histone H3. 
Clavaminate 
synthase domain 
95-336 
Catalytic domain responsible for 
histone demethylation. Predicted  
metalloenzyme domain with cupin 
fold that binds Fe(III) and 
alphaKG. 
28.7 8.33 
MBP/ 
Amylose 
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JMJD2 NM_136487 
Histone demethylase that specifically 
demethylates 'Lys-9' and 'Lys-36' residues 
of histone H3. 
JMJC domain 149-315 
Catalytic domain responsible for 
histone demethylation. Predicted  
metalloenzyme domain with cupin fold 
that binds Fe(III) and alphaKG. 
19.5 6.32 
MBP/ 
Amylose 
ASH1 NM_079436 
Trithorax group (TrxG) protein with 
histone methyltransferase activity, which 
specifically trimethylates 'Lys-4' of 
histone H3 (a specific tag for epigenetic 
transcriptional activation) and to a lesser 
extend trimethylate H3 'Lys-9' and H4 
'Lys-20'. 
BAH domain 1943-2063 
BAH (bromo-adjacent homology) is 
commonly found in chromatin-
associated proteins implicated in 
transcriptional regulation. Acts as 
protein-protein interaction modules. 
14.5 8.26 
MBP/ 
Amylose 
TrX NM_134282 
Histone methyltransferase responsible for 
methylating 'Lys-4' of histone H3 (a 
specific tag for epigenetic transcriptional 
activation). Functions in segment 
determination through interaction with 
genes of bithorax (BX-C) and 
antennapedia (ANT-C) complexes. 
Zinc Finger 1266-1482 
Plant homeodomain (PHD) zinc finger 
domain has a C4HC3-type motif, found 
in many chromatin regulatory factors. 
They can bind zinc and other metal 
ions. Involved in protein-protein and 
protein-DNA interactions, and 
impliaceted in transcriptional 
regulation, translation, chromatin 
remodelling and etc. 
24.3 8.39 
MBP/ 
Amylose 
MBP tag 
(MalE) 
AF097412 Affinity tag N/A 1-400 Maltose binding / Affinity tag 44.0 4.88 N/A 
       
 GenBank ID Protein Function 
Molecular Weight 
(kDa) 
Isoelectric 
point (pI) 
Affinity Tag / Resin used for SELEX 
Reference 
PubMed ID 
NELF-E NM_139984 
Regulation of RNA Pol II elongation, 
maintenance of paused RNA Pol II.  
31.8 9.47 6xHis / Ni-NTA 24453987 
DXO NM_033613 
Exoribonuclease that specifically 
degrades pre-mRNAs with a defective 5'-
cap and is part of a pre-mRNA capping 
quality control. Has decapping, 
pyrophosphohydrolase and 5'-3' 
exonuclease activities. 
45.3 8.29 6xHis / Ni-NTA 23523372 
Ag Rai1 NM_001181112 
Exoribonuclease that specifically 
degrades pre-mRNAs with a defective 5'-
cap and is part of a pre-mRNA capping 
quality control. Has decapping, 
pyrophosphohydrolase and 5'-3' 
exonuclease activities. 
44.5 6.14 6xHis / Ni-NTA 19194460 
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p23 NM_001179683 
Molecular chaperone implicated in gene 
regulation by disassembly of protein-
DNA complexes, which in turn allows 
GCN5 acetyltransferase to prolong the 
dissociated state through lysine 
acetylation.  
24.1 4.46 6xHis / Ni-NTA 23022381 
PNPase 
(wildtype 
and 
S484A 
mutant) 
NM_033109 
Polyribonucleotide nucleotidyltransferase 
1 catalyzes the phosphorolysis of RNA 
processively in the 3'-to-5' direction as 
part of the mitochondrial degradosome 
(mtEXO) complex, also implicated in 
translocatio of nuclear-encoded RNA into 
mitochindria matrix. 
86.0 7.87 6xHis / Ni-NTA 20691904 
6xHis tag AF097413 Ni+2 binding / Affinity tag 3.7 5.42   
       
 GenBank ID Protein Function 
Molecular Weight 
(kDa) 
Isoelectric 
point (pI) 
Affinity Tag / Resin used for SELEX 
Reference 
PubMed ID 
RTF1 NM_015138 
Component of the PAF1 complex 
(PAF1C) which has multiple functions 
during transcription by RNA polymerase 
II and is implicated in regulation of 
development and maintenance of 
embryonic stem cell pluripotency. 
80.3 8.21 FLAG peptide / FLAG M2 resin 26217014 
Flag 
peptide 
tag 
N/A FLAG M2 antibody binding / Affinity tag 2.7 3.97 N/A N/A 
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Figure A.3: Analysis of TIP60-Chromo enriched aptamer clusters through selection rounds and 
cycles. (a) Median multiplicity of top 1,000 TIP60-Chromo aptamer clusters in a given round-
cycle and their median multiplicity in subsequent round-cycles of selection. (b) Number of 
common aptamer clusters in top 1,000 clusters between different round-cycles of selection for 
TIP60-Chromo. Common aptamer clusters from R2C1 to R3C2 with the later round-cycles are 
mostly due to sequence artifacts that pass through our sequence filter criteria. (c) Correlation plots 
for rankings of common aptamers in top 1,000 clusters at different selection cycles for TIP60-
Chromo. R2 values for each correlation are indicated. Multiplicities (reads per million) for 1st, 20th, 
and 1000th cluster in each library are as follows: R2C1 – 130.4, 1.3, 0.5; R2C2 – 184.5, 1.7, 0.6; 
R3C2 – 145.1, 2.5, 0.6; R3C3 – 697.4, 2.4, 1.2; R4C2 – 3,164.8, 610.4, 14.8; R4C3 – 12,038.3, 
1,958.4, 43.6; and R4C4 – 7,923.3, 1,520.1, 35.8. 
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Figure A.4: Binding analysis of candidate aptamer sequences via EMSA. Results from EMSA 
experiments were quantified using ImageJ, and fitted to the Hill Equation using Igor Pro 5.04A. 
 
Figure A.3: Specificity of DXO aptamers. The specificity of DXO aptamers was tested by 
nitrocellulose filter binding assay. Radiolabeled RNA aptamers, DXO #4 and #5, and the N70 
library (negative control) were incubated with varying concentrations (3000-4 nM) of DXO, 
TIP60-Chromo, GCN5-GNAT, MOF-Chromo, or Trx-ZnFinger proteins. Protein bound aptamers 
were captured by a nitrocellulose filter and detected by phosphorimaging. DXO #4 and #5 
aptamers showed very weak binding, indistinguishable from N70 library control, against all other 
target proteins tested. 
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Figure A.4: Predicted secondary structures of DXO aptamers. MEME identified motif (DXO 
motif 1), which base-pairs with the BamHI site in the forward constant region of the N70 RNA 
library, is colored cyan. The predicted secondary structures and the deltaG values were obtained 
from mFold Web Server (http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form). 
 
Figure A.5: Stability of DXO aptamers against DXO exoribonuclease activity. (a) Each 
radiolabeled RNA aptamer was incubated with 1 µM DXO protein and samples collected at 
indicated time points were analyzed by running on an 8% denaturing PAGE gel. The gel image 
was analyzed, and a DXO exoribonuclease assay time course was plotted. (b) Aptamer half-lifes 
(T1/2 min) are estimated from exponential decay function fit to measured % full-length aptamer 
remaining. Images were analyzed by ImageJ and data analysis was done in Microsoft Excel.  
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Figure A.6: Mutant and truncated DXO aptamers. (a) Predicted secondary structure of mutant and 
truncated DXO aptamers. MEME identified motif (DXO motif 1) is colored cyan and mutations 
to motif and the corresponding mutations in the forward constant region are colored red. In mut1, 
the original motif, GGATCCC, was changed to CCTAGGC and the BamHI site, GGATCC, in the 
forward constant region was changed to CCTAGG. In mut2, the original motif, GGATCCC, was 
changed to AATATTC and the BamHI site, GGATCC, in the forward constant region was changed 
to AATATT. Truncations of DXO #2 and #5 were made to retain the DXO motif 1 (cyan) and the 
first stem-loop structure for each aptamer. A sequence-shuffled version of DXO #5 trunc was used 
as a control. Secondary structures were predicted and the deltaG values were calculated by mFold 
Web Server (http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form). (b) Stability (deltaG 
values) of complete predicted structure and the first stem of original full-length, mutant, and 
truncated versions of DXO aptamers. (c) Stability of original, mutant and truncated DXO aptamers 
against DXO exoribonuclease activity. 
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Figure A.7: Inhibition of DXO exoribonuclease activity by RNA Aptamers.  (a) Quantification of 
DXO exoribonuclease activity against 3’-Cy5 labeled 30-nt RNA substrate in the presence of 
indicated concentrations of N70 aptamer pool, or DXO #2, #4, or #5 RNA aptamers from gels 
images shown in Fig. 4d. Data was fitted to a 4-parameter dose-response curve using GraghPad 
Prism6 software, and the estimated IC50 values are listed (b). Errors represent the standard error. 
(c) Verification of equal loading of RNA aptamers, which remained largely intact even after two 
hours of incubation with DXO enzyme, in DXO exoribonuclease inhibition assays. 
 125 
 
 
Figure A.8: Inhibition of DXO exoribonuclease activity by full-length or truncated DXO RNA 
aptamers. A) 3’-Cy5 labeled 30 nt RNA substrate was incubated with 1uM DXO exoribonuclease 
either in the absence of any aptamer (No Aptamer) or in the presence of 0.8 µM full-length or 
truncated DXO RNA aptamers. After 2 hours of incubation at 37°C, exoribonuclease reactions 
were separated by 10% denaturing PAGE, and the remaining intact RNA substrate, indicated by 
, was visualized by Cy5 fluorescence scan. B) Percentage of full-length DXO substrate 
remaining under each condition as quantified by ImageJ.   
 
